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FOREWORD 
 
The International Council for Laboratory Animal Science was organized in 
1956, at the initiative ofthe United Nations Educational, Scientific and Cultural 
Organization (UNESCO), the Council for International Organization of Medical 
Science (CIOMS) and the International Union of Biomedical Sciences (IUBS).  
ICLAS is an international non-governmental and non-profit-making scientific 
organization. The aims of ICLAS are to promote international collaboration, quality 
monitoring and definition of laboratory animals, to collect and disseminate 
information and to promote the human use of animals in research through recognition 
of ethical principles and scientific responsibilities.  
ICLAS has been stressing the importance of complementary and alter- native 
methods since a long time and the time has carne to ask the question how far we can 
go in the use of these methods. Careful planning, refinement of techniques, the rapidly 
expanding field of biotechnology and the development of non-mammalian models 
such as monoclonal antibodies and recombinant DNA technology, can lead to the 
reduction in the number of animals needed to obtain statistically significant answers 
and to the reduction of animal pain. There is however no chance of replacing all 
animals in research and testing in the foreseeable future. The search for alternative 
methods should continue but the hope for a certain success must be tempered by the 
realization that progress in this area has been slow.  
The Governing Board ofICLAS decided in Hyderabad in September 1994 to 
create a working group on complementary and alternative methods with Dr . de la 
Peña de Torres as coordinator. The workshop on complementary methods organized in 
the Centro de Salud Pública Talavera dé la Reina Toledo from 27 through 30 
April1995 was the first concrete action of this ICLAS working group.  
Several ,well-known scientists participated to this working group which was of a 
high scientific quality. The following general topics were discussed by the working 
group: in vitro cytotoxicity test; in vitro test for carcino- gen/mutagen detection; in 
vitro test for eye/skin irritancy and in vitro test for organ-specific toxicity. I really 
hope that this workshop will contribute significantly to the reduction of the number of 
animals used in testing.  
I would like to thank very much the organizing committee of this working group 
and in particular his coordinator Dr. de la Peña de Torres for the work they have 
achieved.  
 
 
   Prof. J.R. Maisin  
   President of ICLAS  
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ICLAS  
 
ICLAS is a non-governmental organization for international cooperation in 
laboratory animal science. Its aims are to promote international collaboration, 
quality monitoring and definition of laboratory animals, to collect and 
disseminate information and to promote the humane use of animals in research 
through recognition of ethical principIes and scientific responsabilities.  
 
ICLAS was organized in 1956 at the initiative of UNESCO, CIOMS and 
IUBS. Since 1961 ICLAS has been officially recognized by the WHO and more 
recently by ICSU and WVA.  
 
ICLAS has National Scientific, Union, and Associate members. National 
members represent national authorities and the Scientific members are repre- 
sentatives of different national and regional laboratory animal science associ- 
ations. Union members represent international non-governmental unions, and the 
Associate members are commercial and other organizations and institutes which 
support the aims of ICLAS.  
 
Number of members in December 1994: 8 Honorary, 41 National, 19 Sci- 
entific, 8 Union, 68 Associate members.  
 
 
CSIC  
 
Spain's Scientific Research Council (Consejo Superior de Investigaciones 
Científicas), best known by its acronym, CSIC, was founded in 1939.  
 
While belonging to the Ministry of Education and Science, the CSIC is at 
the same time an autonomous body with its own assets and bylaws. It is the most 
important multidisciplinary research centre in Spain and one of its basic 
functions is the furtherance of science within its member institutes.  
 
The CSIC has 94 institutes distributed throughout Spain. 39 are in the 
province of Madrid, 16 in Andalucía, 13 in Cata1onia, 6 in Valencia, 5 in 
Aragón, 4 in Galicia, 3 in Castilla-León, 2 in the Canary Islands, 2 in Asturias, 1 
in Murcia, 1 in the Balearic Islands and 1 in Cantabria. It also has an institute in 
Rome (Italy). The majority of these research centres belong entirely to the CSIC, 
but 23 of them are operated on a joint basis with universities.  
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TABLE 1 
Classification of Alternative Methods 
 In vitro techniques -Embryo culture  
 -Organ culture and baths  
 -Culture of cell reaggregates  
 -Culture of dispersed cells   
 -Culture of cell lines -Cell free models  
 -Lower organisms: bacteria, algae, etc.  
 
 Theoretical prediction models 
  -Relation chemical structure activity (QSAR)  
 -Pharmaco-toxicocynetics (PB- PK ) 
 
 Teaching models  
 -Mechanical models  
 -Audiovisual systems  
 -Computer simulation and virtual reality  
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• Dr. Herman KÖETER, Health and Environmental Security Division of the 
OECD.  
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available to us.  
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BACKGROUND OF ICLAS  
 The opportunity to hold this Working Group, Talavera '95.  
  
 ICLAS (International Council on Laboratory Animal Science) has been 
stressing the importance of complementary and alternative methods to animal 
experimentation for years now. In the ICLAS Regional Meeting held in Madrid 
(1982), several presentations were presented on bioassays methods on 
complementary or alternative methods. In 1983, the ICLAS/CSIC Spanish 
Committee, in collaboration with the General Councils of Pharmacists, 
Medical Doctors and Medical Veterinaries, published a list of Ethical 
Principles in Animal Experimentation (Figure 1).  Article 7 and this list makes 
reference to the use of Complementary / Alternative Methods to Animal 
Experimentation. In the ICLAS Regional Meeting held in Aguas de Lindoia 
(Brazil) we made a presentation on complementary methods entitled " 
Alternatives to animal experiments in the toxicology and ecotoxicology 
research program" (Laborda, de la Peña et al. 1986). More recently, during the 
last ICLAS Regional Scientific Meeting held in Hyderabad (India), the 
president of ICLAS, Prof. Maisin, in his inaugural presentation made special 
mention of the development of complementary methods as well as the 
important work being done by ECVAM, European Centre for the Validation of 
Alternative Methods, Environment Institute in the Joint Research Centre of 
Ispra, Italy (Maisin, 1994).  
 
 The importance of the development of new complementary methods led to 
the creation of the Working Group on Complementary Methods during the 
ICLAS board of directors meeting in Hyderabad. I was made responsible for 
the coordination of this group and it is my hope that we get a lot accomplished 
in this working group. The conclusions and agreements reached here were 
presented in July of this year in the Helsinki Assembly and Congress.  
 
SOCIAL CALL FOR COMPLEMENTARY ASSAYS  
 Today's society is calling for assays which use less animals or which use no 
animals at all. This call is the social answer to the three Rs proposed by Rusell 
and Burch (1959):  
 1) Reduction in the number of animals used.  
 2)  Refinement of the assays in which animals are used. 
3) Replacement of assays which use animals.  
 
VALIDATION OF COMPLEMENTARY METHODS  
 This validation can be considered from a scientific, political and 
commercial point of view with regard to evaluation, replacement and other 
aspects (Balls, 1994).  
ICLAS/CSIC WORKING GROUP ON COMPLEMENTARY METHODS 23
 The validation of assays touches upon three fundamental aspects:  
 
 1)  Selection of the chemical compounds used in the validation process;  
 
 2)  Availability of in vivo data to be used as a point of reference when 
assessing the in vitro results; 
  
 3) The method used to analyze, compare and interpret in vivo and in vitro 
data.  
 
ACCEPTANCE OF COMPLEMENTARY METHODS  
 
 They must be legally approved before they can be used to test chemical and 
pharmaceutical substances. This stage of legal acceptance follows intra and 
inter-laboratory confirmation and the development of a data base which 
comprises the validation process.  
 
 In this area, the 15 Recommendations of the CAAT/ERGATT Workshop 
on the Validation of Toxicity Test Procedures (Balls et al. 1990) should be 
considered.  
 
 The OECD has drawn up a series of monographs on validation as well as 
methods guides: Scientific Criteria for Validation on in vitro Toxicity Test 
(OECD 1990), and Guidance Document for the Development of OECD 
Guidelines for Testing of Chemicals (OECD, 1993).  
 
LEGISLATION  
 
 The legislation concerning complementary and alternative methods to the 
use of laboratory animals (EEC Directive 86/609) makes mention of the use of 
alternative methods in articles 7 and 23 and in the March 14 Royal Decree 
223/1988, on the protection of laboratory animals used for experiments and 
other scientific purposes (BOE Boletín Oficial del Estado, 18 March, 1988); in 
the Community of Madrid, the Office of Agriculture and Cooperation emitted 
an order (4 August, 1989) concerning the protection of animals used for 
experiments and for other scientific purposes (BOCM Boletín Oficial de la 
Comunidad de Madrid, 24 August, 1989).  
 
 The EEC Directive 93/35 on cosmetics sets the date of January 1998 as the 
deadline for the use of laboratory animals in the evaluation of the toxicology of 
their components given that alternative methods exist.  
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 DEVELOPMENT OF THE WORKING GROUP  
 
 The ICLAS/CSIC Working Group on Comp1ementary Methods was 
divided into five work sessions, each of which began with a presentation by an 
invited speaker. The subjects and speakers were as fo11ows:  
 
 • Session I/Speaker Dr. Herman Köeter. International Harmonization of 
Test Methods for Hazard Characterisation Taking Into Account Animal 
We/fare Issues.  
 • Session II / Speaker Dr. Horst Spielmann. The Validation of in vitro 
Toxicity Test Procedures in Europe.  
 • Session III / Speaker Dr. Ma José Gómez Lechón. In vitro Assays in the 
Development of Drugs and Chemicals.  
 • Session IV / Speaker Dr. A1an Goldberg. Development of Alternative 
Methods and the Modular Approach to Validation.  
 • Session V / Speaker Dr. Michae1 Bal1s The Development, Validation and 
Acceptance of Alternative Methods.  
 
 The presentation made by each one of the speakers was fo11owed by a 
discussion that was summarized by the rapporteurs and moderators of each 
session in order to put together a work document. The summaries were agreed 
upon in session VI.  
 
 • Session VI/ Overall Review, Summary and Conc1usions. Secretary, Dr. 
Gonzá1ez Menció. Rapporteurs, H. Spie1mann, A. Lopez de Ceraín and 
C. Barrueco.  
 
Conclusions and Clausure  
 
 The following is a 1ist of the general aspects to be considered throughout 
the Working Group on Comp1ementary and/or A1ternative Assays:  
 
 1) In vitro cytotoxicity test.  
 2) In vitro test for carcinogen/mutagen detection.  
 3) In vitro test for eye/skin irritancy (Draze irritancy test).  
 4) In vitro test for organ-specific toxicity.  
4 
 It wou1d 1ike to thank each one of the participants for his/her effort and to 
the members of the organization committee for their work before and during 
the meeting.  
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Figure 1 
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS 
lnternational Council for Laboratory Animal Science 
COMITE ESPAÑOL DEL ICLAS/CSIC 
PRINCIPIOS ETICOS DE LA EXPERIMENTACION ANIMAL 
 
Principios básicos  
 
Artículo 1. Los progresos del conocimiento humano, son necesarios y sobre todo los de la
biología, de la medicina del hombre y de los animales.  
Articulo 2. El hombre tiene necesidad de utilizar el animal en la búsqueda del conocimiento
humano igual que para alimentarse, vestirse y trabajar. De ahí el deber de respetar el
animal, entre auxiliar y ser viviente común a él.  
Artículo 3. Toda persona que emplee animales con fines experimentales debe tener presente
que están dotados de sensibilidad y memoria y son susceptibles al dolor y sufrimiento.  
 
Responsabilidades del experimentador  
 
Artículo 4. El experimentador es moralmente responsable de sus actos en el marco de la
 experimentación animal.  
Artículo 5. Las experiencias concernientes a los seres vivos y las extracciones de tejidos a
sujetos vivos con fines de investigación deben ser realizados por un científico cualificado
o bajo su control directo. Las condiciones de conservación de los animales en
experimentación deben ser definidas y controladas por un veterinario o por un científico
competente.  
Artículo 6. En los estudios sobre la utilización de animales debe existir una probabilidad
razonable para que estos estudios contribuyan de manera importante a la adquisición de
conocimientos que desembocan eventualmente en la mejora de la salud y del bien- estar
del hombre y de los animales.  
Artículo 7. Los métodos estadísticos, los modelos matemáticos y los sistemas biológicos in
vitro deben ser utilizados cuando sean apropiados para completar la experimentación
animal y para reducir el número de los sujetos utilizados.  
Artículo 8. El experimentador debe utilizar el animal mejor adaptado a su investigación y
tener en cuenta también los grados sensoriales y psíquicos propios de cada especie. Los
animales en peligro de extinción no deberán ser utilizados más que en circunstancias
excepcionales muy definidas. Mientras sea posible, los animales utilizados en el
laboratorio provendrán de crías especializadas para asegurar las mejores condiciones de
equilibrio biológico.  
Artículo 9. El experimentador debe velar porque las condiciones de conservación del animal
de laboratorio sean las mejores posibles y aportar los cuidados necesarios antes, durante y
después de las intervenciones.  
Artículo 10. El experimentador tiene el deber de ahorrar al animal todo sufrimiento fisico o
psíquico inútil. Debe poner en marcha los métodos que permitan limitar el sufrimiento y
los dolores en el caso o casos que sean inevitables.  
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INTERNATIONAL HARMONIZATION OF TEST METHODS 
FOR HAZARD CHARACTERISATION TAKING INTO 
ACCOUNT ANIMAL WELFARE ISSUES 
 
Herman B.W.M. Köeter1, Principal Administrator,  
OECD Environmental Health and Safety Division,  
2, rue Andre-Pascal, 75775 Paris Cedex 16, France  
 
INTRODUCTION  
 
 Today, some 100,000 chemicals are in commercial use. Fifteen hundred of 
these chemicals are considered as High Production Volume (HPV) chemicals 
with a yearly production of more than 10,000 tons each. Of these HPV 
chemicals, some 500 are identified for which little or no data is available in the 
open literature. In order to decrease the number of (potentially) hazardous 
compounds on the market, regulation of new chemical entities generally in- 
volves a substantial number of toxicity tests. In addition, the OECD countries 
decided in 1987 to undertake a systematic investigation of existing chemicals. 
Both activities include toxicity testing.  
 
HAZARD IDENTIFICATION:  
SOME GENERAL CONSIDERATIONS  
 
 The most fundamental question, being the comerstone of chemical man- 
agement, is: what are acceptable risks of chemical exposure? In order to be 
able to answer this question, one must first identify the potential hazards and 
classical tools of the hazard identification process still are animal studies.  
 
 Principles that are considered most relevant in toxicity testing in general 
are:  
 
 • Identification of the nature of the toxic effect (qualitative approach);  
 • Assessment of the dose needed to induce the toxic effect (quantitative 
approach);  
 • Understanding the mechanism underlying the toxic effect (mechanistic 
approach).
                                                 
1 The opinions presented in this paper do not necessarily represent the opinions of the OECD or its 
Member countries and should therefore be viewed as those of the author.  
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 In general, animal studies required for regulatory purposes only address the 
first two aspects. Although this information indeed is of crucial importance as 
the basis for human safety evaluation (Hart and Fishbein, 1985), it is in many 
ways deficient. The toxicologica1 expression of a chemical insu1t may vary 
between species including man or be species-specific. Next, the dose needed to 
induce an adverse effect mostly relates to dosages given to the animals rather 
than concentration at the site of action (target organ). As a consequence, un- 
certainty factors being a clear expression of the inability of the toxicologist to 
scientifically determine the human hazard of a defined exposure, are still nec- 
essary in hazard assessment procedures. Consequently, information about the 
underlying mechanism of toxic action, including knowledge of the metabolic 
fate of the chemical substance in the animal species tested, would reduce or 
occasionally even eliminate these uncertainty factors.  
 
 Today a variety of animal studies is available covering acute, repeated- 
dose and long-term toxicity, carcinogenicity, neurotoxicity, immunotoxicity 
and genetic and reproductive toxicity. An overview of all currently available 
OECD Test Guidelines in the area of human effects assessment is presented in  
Table 1.  
 
TABLE 1: ADOPTED OECD TEST GUIDELINES ON HEALTH EFFECTS  
 
No Title Date of Adoption 
401 Acute Oral Toxicity  24 February 1987 
402 Acute Dermal Toxicity  24 February 1987 
403 Acute Inhalation Toxicity  12 May 1981 
404 Acute Dermal Irritation/Corrosion  17 July 1992 
405 Acute Eye Irritation/Corrosion  24 February 1987 
406 Skin Sensitisation  17 July 1992 
407 Repeated Dose 28-day Oral Toxicity in Rodents  27 July 1995 
408 Subchronic Oral Toxicity -Rodent: 90-Day  12 May 1981 
409 Subchronic Oral Toxicity -Non-Rodent: 90-Day  12 May 1981 
410 Repeated Dose Dermal Toxicity: 21/28-Day  12 May 1981 
411 Subchronic Dermal Toxicity: 90-Day 12 May 1981 
412 Repeated Dose Inhalation Toxicity: 28/14-Day  12 May 1981 
413 Subchronic Inhalation Toxicity: 90-Day 12 May 1981 
414 Teratogenicity 12 May 1981 
415 One-Generation Reproduction Toxicity 26 May 1983 
416 Two-Generation Reproduction Toxicity 26 May 1983 
417 Toxicokinetics  4 April 1984 
 
418 
 
Delayed Neurotoxicity of Organophosphorus Substances 
following Acute Exposure  
 
27 July 1995 
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No. 
 
Title 
 
 
Date of Adoption 
 
419 
 
De1ayed Neurotoxicity of Organophosphorus Substances: 2º8-
day. Repeated Dose Study  
 
27 July 1995 
 
420 
 
Acute Oral Toxicity -Fixed Dose Method  
 
17 July 1992 
 
421 
 
Reproduction/Developmental  
Toxicity Screening Test  
 
27 July 1995 
 
451 
 
Carcinogenicity Studies  
 
12 May 1981 
 
452 
 
Chronic Toxicity Studies  
 
12 May 1981 
 
453 
 
Combined Chronic Toxicity/Carcinogenicity Studies  
 
12 May 1981 
 
471 
 
Genetic Toxicology: Salmonella typhimurium, Reverse 
Mutation Assay  
 
26 May 1983 
 
472 
 
Genetic Toxicology: Escherichia coli, Reverse  
Mutation Assay  
 
26 May 1983 
 
473 
 
Genetic Toxicology: In vitro Mammalian Cytogenetic Test  
 
26 May 1983 
 
474 
 
Genetic Toxicology: Micronucleus Test  
 
26 May 1983 
 
475 
 
Genetic Toxicology: In vivo Mammalian Bone Marrow 
Cytogenetic Test -Chromosomal Analysis  
 
4 April 1984 
 
476 
 
Genetic Toxicology: In vitro Mammalian Cell Gene  
Mutation Tests  
 
4 April 1984 
 
477 
 
Genetic Toxicology: Sex-Linked Recessive Lethal Test in 
Drosophila melanogaster .  
 
4 April 1984 
 
478 
 
Genetic Toxicology: Rodent Dominant Lethal Test  
 
4 April 1984 
 
479 
 
Genetic Toxicology: In vitro Sister Chromatid Exchange 
Assay in Mammalian Cells  
 
6 October 1986 
 
480 
 
Genetic Toxicology: Saccharomyces cerevisiae, Gene 
Mutation Assay  
 
6 October 1986 
 
481 
 
Genetic Toxicology: Saccharomyces cerevisiae, Mitotic 
Recombination Assay  
 
6 October 1986 
 
482 
 
Genetic Toxicology: DNA Damage and Repair, Unscheduled 
DNA Synthesis in Mammalian Cells in vitro  
 
6 October 1986 
 
483 
 
Genetic Toxicology: Mammalian Germ Cell Cytogenetic 
Assay 
 
6 October 1986 
 
484 
 
Genetic Toxicology: Mouse Spot Test  
 
6 October 1986 
 
485 
 
Genetic Toxicology: Mouse Heritable Translocation Assay  
 
 
6 October 1986 
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OECD TEST GUIDELINES PROGRAMME  
 
 The OECD Test Guidelines are considered the leading international stan- 
dard for safety testing and, indeed, are an important activity of the OECD. 
Consequently, alternative test methods, either using smaller numbers of ani- 
mals, or using in vitro techniques, once adopted by OECD, would carry con- 
siderable weight and lead to the fervidly desired international acceptance. In 
order to increase the awareness of the possibilities that exist to give input to the 
Test Guidelines Programme and, in particular, to support the development of 
alternative (in vitro) test methods, a full understanding of the programme is 
essential. Although the OECD Test Guidelines as such are well-known, it is 
certainly less known how these guidelines are developed. To this end, a 
monograph has been drafted, explaining the structure of the Test Guidelines 
Programme, the various levels of responsibility and ways of giving input to the 
Programme (OECD, 1993a).  
 
 An essential aspect of the OECD is that this organisation is not a supra- 
national organisation but rather a center for discussion where governments 
express their points of view, share their experiences and search for common 
ground. This implies that decisions  are made by consensus. Once the Coun- 
cil, which is the highest authority of the OECD, adopts a formal Decision such 
a decision is binding on all Member countries. The OECD Guidelines for the 
Testing of Chemicals (OECD, 1993b) form an integrated part of such a binding 
Council Decision (OECD, 1981). The other subject of this Council Decision, 
which is less known is that on Mutual Acceptance of Data. In the Council 
Decision it is stated that: "Data generated in the testing of chemicals in an 
OECD Member country in accordance with OECD Test Guidelines and OECD 
Principles of Good Laboratory Practice (GLP) shall be accepted in other 
Member countries for purposes of assessment and other use relating to the 
protection of man and the environment". In cases where this OECD Decision 
has not been complied with by an OECD Member country, a specific form 
could be used to inform the OECD Secretariat of such a case (OECD 
Notification of Incomplete Implementation of the OECD Decision on Mutual 
Acceptance of Data). The information provided will be kept confidential and 
the Environmental Health and Safety Division of the OECD Secretariat will 
conduct an investigation of the complaint in the Member country involved.  
 
 The process of Test Guideline development comprises two parts. First, the 
need for a guideline is to be defined. The various steps of this part of the 
process are indicated in Figure 1.  
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              Figure 1: OECD Test Guideline development; Step 1: defining the need. 
 
 
 
TABLE 2. Criteria for considering a test guideline 
proposal for development as OECD Test Guideline. 
 
 
 
 
 
 
 
 
 
 
 
  
 • The  proposed  test  should  properly  address  the  end- points concerned, 
 
• in addition, the proposed test should have undergone a
critical appraisal concerning its:  
 
• scientific justification,  
 • sensitivity,  
• reproducibility,  
 
including, where feasible and relevant, a comparative  
study, supporting the validity of the test proposed,  
 
• further, the test should allow for standardization, and  
 
 • not normally require unique equipment or technical ex- 
 perience. 
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As clearly indicated in this diagram, the National Co-ordinators of the Test 
Guidelines Programme play an important role in this process. The initiative to 
start the development of a particular guideline can be taken by the OECD 
Secretariat,  by  one  or more  Member  countries  or,  most  importantly,  by 
the scientific community itself. Proposals, received by the Secretariat are 
discussed at the annual Meeting of National Co-ordinators. During these 
meetings,  priorities for future activities are set and the approach that should be  
followed in dealing with the selected activities is discussed. Quite often, SO- 
called Detailed Review Papers (DRPs) form the basis of a new or updated 
guideline. These DRPs, which are either prepared by a Member country or by a 
consultant appointed by the Secretariat, describe the current state-of-the- art in 
scientific progress and technical possibilities of a well-defined area of research.  
    
      
 
Figure 2. OECD Test Guideline development; Step 2: producing the product. 
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 After completion, either an expert meeting or a commenting round will be 
organised. All Member  countries will have sufficient  opportunities to ex- 
press their views. When the DRP is acceptable to the experts of all Member 
countries, the second part is the actual development of a Test Guideline, based 
on  recommendations  as included  in the  DRP.  When  the  need to  develop or  
update a Test Guideline is clear-cut, the OECD Secretariat may arrange for the 
preparation  of a draft  Test  Guideline  proposal  without a  DRP.  The crite- 
ria that apply in order to consider a proposal for development as OECD Test 
Guideline are presented in Table 2.  
Not surprisingly, the most relevant criterion, being the validity of the test 
proposed, is, at the same time, the most difficult one to demonstrate. The part 
of the process that describes the procedure of actual Test Guideline 
development is indicated in Figure 2. Similar to the procedure followed for the 
DRP, the Test Guideline proposal will be circulated for comment to relevant 
experts in all Member countries nominated by their National Co-ordinator. 
Frequently, in addition to the commenting rounds, Test Guideline proposals are 
discussed in special expert meetings. Once the experts reach consensus on a 
particular Test Guideline, the proposal is put forward to the Meeting of the 
National Coordinators for approval. Since each Guideline will form an 
integrated part of the earlier mentioned Council Decision, each Guideline also 
needs formal adoption by the Council before it becomes effective.  
 
OECD AND ANIMAL WELFARE  
With respect to animal welfare, the OECD has taken a rather pragmatic 
position. At the second High Level Meeting in 1982, bringing together minis- 
ters and other high level officials, the following statement was adopted: " The 
welfare of laboratory animals is an important factor influencing the work in 
the OECD Chemicals Programme. The progress in OECD on the harmoniza- 
tion of chemicals control, in particular the agreement on mutual acceptance of 
data, by reducing duplicative testing, will do much to reduce the number of 
animals used in testing. Such testing cannot be eliminated at present, but ev- 
ery effort should be made to discover, develop and validate alternative testing 
systems" (emphasis added). In 1987, when some existing guidelines on health 
effects were updated, animal welfare was addressed indeed. As a result the 
number of animals required for acute toxicity testing was reduced and the 
probability of severe animal suffering was diminished (Updated Test Guide- 
lines 401, 402 and 405). At the same time, the updated Test Guideline on 
Acute Eye Irritation/Corrosion (Test Guideline 405) provided for the use of 
well-validated alternative studies to identify corrosive or severe irritating sub- 
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stances. Now, substances recognized as such in the alternative test need not be 
further tested for eye irritation, it being presumed that such substances will 
produce similarly severe effects on the eyes in a live animal test. Because the 
High Level Meeting of 1982 had recommended that alternative methods be 
validated before they can be applied in hazard identification schemes, there 
was a need to define the scientific criteria for validation of alternative meth- 
ods. In a document on this subject prepared for the OECD, Frazier (1990) 
describes a three-step approach consisting of: micro (intralaboratory) valida- 
tion, macro (interlaboratory) validation, and test battery optimization (given 
several test systems, compose the most relevant combination). In the report of 
the CAAT IERGATT Workshop on the validation of toxicity test procedures 
more or less the same strategy was recommended (Balls et al, 1990). CAAT is 
The Johns Hopkins Center for Alternatives to Animal Testing and ERGATT is 
the European Research Group on Altematives to Animal Testing. However, 
this Workshop expanded the validation scheme with a "test data base devel- 
opment phase". Further, they made clear recommendations with respect to the 
numbers of reference chemicals that should be tested at each phase, in total 
amounting to as many as 235-330 compounds. Recently, again under the 
auspices of CAAT and ERGATT , a follow-up workshop on the issue of 
validation concluded that the criteria for validation should be more flexible. 
(Balls et. al., 1995).  
Most papers that deal with the issue of test validation focus on the need to 
show reproducibility and high correlations with the existing animal test they 
want to replace. The higher the number of chemicals tested and the bigger the 
number of participating laboratories, the better the validation project. From a 
statistical viewpoint this may certainly be true. However, not only is such a 
validation process very time-consurning and extremely expensive, it also lacks 
the fundamental basis of proving mechanistic similarity to the phenomenon we 
want to study.  In other words,  when one  wants to  assess a  particular hazard 
(either human or environmental), the question should be asked: does the 
alternative test give sufficient information to be able to make such an assess- 
ment? Reasoning along these lines, Flint (1992) even suggested applying only 
one rule for validation, namely: " Al[ tests must have demonstrable mechanis- 
tic similarity to the events we wish to study in vivo". Although this approach 
rightly puts necessary emphasis on the importance of the fundamental sci- 
entific principle of acceptance of alternative lÍ1ethods by understanding the 
mechanisms involved, it will nevertheless also remain necessary to prove the 
reproducibility of a promising method.  
In order to avoid confusing the issue and cause further delay, the philoso- 
phy of learning by doing could be adopted. This rather pragmatic approach has 
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proved to be successful in the OECD Existing Chemicals Programme (Brydon 
et al, 1990). In this context it would mean that incorporating "alternative" test 
methods in safety testing programmes, not to the exclusion but in addition to 
animal studies, even when they are not (fully) validated, will offer the 
possibility of a better understanding of the potential and limitations of the 
selected alternative under various test conditions. At the same time a valuable 
data base could be developed. Such parallel or tiered testing may appear to be a 
practical and more realistic way of demonstrating the quality (the intrinsic 
value, sensitivity, reproducibility, and selectivity) of se1ected alternative tests.  
Consequently, in the updated version of the Test Guideline 404 on Acute 
Dermal Irritation/Corrosion, and Test Guideline 406 on Skin Sensitisation, 
adopted by the OECD Council in July, 1992, there is now room for alterna- 
tive  methods  that  are not  (yet)  formally  validated.  In  Test  Guideline 404 
it is  stated  that  "it may  not be  necessary  to test  in vivo  materials  for which 
corrosive properties are predicted on the basis of results from in vitro tests". 
Similarly, Test Guideline 406 allows the use of initial, less-invasive animal 
screens to detect sensitizing substances. However, as conditio sine qua non 
each alternative test should be conducted fully in compliance with the Prin- 
ciples of Good Laboratory Practice (GLP) and be similarly reported as a full 
animal study.  
 
Regulatory Acceptance of Alternative (In Vitro) Tests  
 A scenario for the development of in vitro tests that could be followed with 
a reasonable chance of international regulatory acceptance, is summarized in 
Table 3. The approach consists of a number of subsequent steps. Most im- 
portantly, it should be understood that it is of crucial importance to recognize 
and develop simple, differentiated endpoints, essential for hazard identifica- 
tion. For instance, an in vitro assay should address a clearly defined endpoint 
rather than covering in one test all the phenomena of the in vivo endpoints. 
Complex processes which are already difficult to understand in in vivo studies, 
can never be transposed as such to in vitro studies. It should be realized that 
considerable numbers of in vitro assays are necessary to fully cover a particu- 
lar in vivo event. Next, during the process of developing an in vitro method, the 
mechanism of the test should be understood and the significance of its 
endpoints as indicators of adverse effects on the actual target event should be 
considered. This implies that the in vitro test should not in the first place seek 
high correlations with an existing in vivo assay, but mimic as close as possible 
a particular aspect of the real event for which the hazard should be assessed. 
Having accomplished this, the method should be submitted for publication. 
Only acceptance of the paper by a high quality, peer reviewed toxicology jour- 
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nal could be considered as the scientific justification of the test. This strong 
foundation is essential for further development and international acceptance of 
the test.  
In order to develop a sound database, the in vitro assay(s) initially should 
be conducted parallel to the relevant in vivo studies as an integrated part of the 
set of safety evaluation studies, as required by regulatory authorities. In this 
respect, an important role could be played by industry and contract lab- 
oratories, where extensive experience is available with safety evaluation stud- 
ies, conducted under various conditions, by various dose routes and in various 
species. In addition, full knowledge of the toxicity profile of a compound under 
study is almost indispensable for a meaningful interpretation of an observed 
effect, be it an in vivo or in vitro study. A crucial step of this scenario for in 
vitro test development is that the alternative tests be reported, interpreted and 
subsequently integrated in the notification dossier that is submitted to 
regulatory authorities. Consequently, like all in vivo studies, all alternative tests 
should be conducted and reported fully in compliance with GLP.  
 A database  developed  as described  above  does not  necessarily need to 
be of a  particular  size, set in  advance.  By  scientific  judgement,  it  could  be  
decided when sufficient data has been collected to demonstrate that the in vitro 
assay indeed covers a particular event for which the hazard of chemical 
exposure needs to be identified, \hat test results are reproducible, and that the 
assay has proven to be sufficiently sensitive under various conditions. As the 
final step of the scenario, the alternative test(s) should be proposed to the 
OECD to be considered for Test Guideline development, which would be the 
best possible means to achieve international acceptance. 
 
TABLE 3. Approach for the development of alternative (in vitro) test  
methods that could possibly lead to regulatory acceptance 
 
 
SCIENTIFIC 
 
JUSTIFICATION 
 
1. Select simple endpoints essential for hazard identification. 
 
2. Develop in vitro assays for these endpoints.  
 
3. Understand the mechanism of the in vitro assay and demonstrate 
 similarities to the target event.  
 
4.  Publish the assay(s) in a high quality peer-reviewed journal. 
 
 
DATABASE 
 
DEVELOPMENT 
 
5.  Conduct the in vitro assays parallel to the relevant in vivo studies.  
 
6.  Conduct and report all studies fully in compliance with GLP.  
 
7. Integrate results of the in vitro assays in dossiers submitted to 
 regulatory agencies. 
 
 
INTERNATIONAL
ACCEPTANCE 
 
8. Propose the in vitro assay(s) to the OECD to be considered for Test 
 Guideline Development.  
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PERSPECTIVES  
In the short run, the acceptance of alternative tests may well lead to a 
minor reduction of animals in existing in vitro studies and may even lead to the 
"extinction" of some of the most objectionable animal tests. However, the 
policy of replacing existing live animal studies by alternative methods will 
most probably never lead to a dramatic reduction of the number of animal used 
for hazard identification purposes. This seemingly pessimistic viewpoint may 
be explained by using the following metaphor (Köeter, 1991). The most 
complete set of toxicity data on the basis of which hazard assessment is made, 
could be compared with the picture of a completed jigsaw puzzle. Each piece 
of this jigsaw represents a particular study, and the picture informs us about the 
hazard. To keep the picture complete either all original pieces of the jigsaw 
should be collected and fit together or worn-out, lost or discarded pieces should 
be replaced by new ones (alternative tests) that should fit exactly. This very 
time consuming process will at best result in exactly the same picture that we 
had before. In other words, no scientific progress as far as hazard assessment is 
concerned. A better approach, however, would be to keep the old jigsaw, 
preferably patched up by replacing the most worn-out pieces and, at the same 
time, create a completely new jigsaw. This new puzzle, when completed, will 
show a different and probably nicer picture. Moreover, the fine details of this 
new picture may well be of a better quality than those of the old puzzle. As a 
result, the new picture could very well be much better scientific basis for future 
hazard assessment of chemicals. It should be clear, however, that toxicological 
research, aimed at the development of such new endpoints as part of the future 
set of toxicity data will differ from research aimed solely at the substitution of 
a particular test. First, there is no need to cover exactly the same endpoints as 
measured in vivo; second, the research could be focused on understanding of 
mechanisms involved, rather than on evaluating symptoms only. Consequently, 
future hazard assessment will be based not primarily on descriptive science, but 
principally on the understanding of mechanisms at the molecular, cellular and 
tissue level.  
 Simultaneously with this long term policy, the development of alterna- 
tives to existing tests and the subsequent validation of these new tests should 
be continued because it will take considerable time before the old jigsaw 
puzzle can be thrown away. And it certainly needs some repair in order to 
allow its further use! 
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SUMMARY  
In 1989 the "Center for Documentation and Evaluation of Alternative 
Methods to Animal Experiments" (ZEBET) was established at the Institute of 
Veterinary Medicine of the Federal Health Office (BGA) in Berlin. ZEBET is 
not only responsible for the documentation of alternative methods but also for 
validation and acceptance of the new methods at the national and inter- 
nationallevel, e.g. by the EU or OECD.  
THE VALIDATION OF IN VITRO TOXICITY TEST 48
In 1992 the European Centre for Va1idation of Altemative methods (EC- 
VAM) was established at the European Joint Research Centre (JRC) in Ispra 
(Italy). ECVAM is promoting and funding validation activities at the Euro- 
pean level. ECVAM has set standards for the formal validation process and 
ECVAM tries to harmonise them in cooperation with intenational scientific and 
regulatory bodies. In close cooperation ZEBET and ECVAM have managed 
and participated in several European validation studies on altematives to the 
Draize rabbit's eye test and on in vitro testing procedures for phototoxicity and 
corrosivity. At the national level ZEBET promotes the replacement of a fish 
test for waste water by a fish cell cytotoxicity test. Both ECVAM and ZEBET 
are actively promoting the standardization of biostatistics to be used in 
development, validation and evaluation of in vitro test procedures.  
INTRODUCTION  
 
 At the international level there has been growing concern about the suf- 
fering of animals in toxicological testing for regulatory purposes. The first step 
to reduce animal numbers in regulatory testing was intenational standardiza- 
tion of animal test procedures in toxicology by the OECD in 1981 (OECD, 
1981) and an agreement of mutual acceptance of studies carried out according 
to these guidelines by OECD members states including the European Union 
(EU). The next consequent step in reducing the use of animals in toxicological 
testing is the replacement of these tests by in vitro test procedures, which have 
to prove to be valid by undergoing a rigid and formal validation process. 
During the past decade in Europe scientists in academia and industry as well as 
regulators have agreed upon a formal validation process which is both time 
consuming and expensive. Therefore, only the most promising in vitro assays 
could be validated in intemational ring trials so far. The general approach of 
validation will be outlined in the present report and a few characteristic 
examples will be given.  
RESULTS  
Guidelines for the validation of toxicity test procedures  
 
 Since scientific validation of toxicity test procedures had not adequately 
been addressed in 1990 European and American scientists held a joint work-
shop and agreed upon recommendations for the formal validation of toxicity 
test procedures (Balls et al., 1990). These recommendations have been widely 
accepted and, whenever possible, in Europe validation trials were conducted 
accordingly. Taking into account the experience gained in several European 
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validation trials the new European Validation Centre ECVAM sponsored in 
1994 a workshop on practica1 aspects of the va1idation of toxicity test pro- 
cedures to reconsider the theoretical basis for validation (Balls et al., 1995). 
Since in several of the expensive and time consuming validation studies tests 
had been included, which had not sufficiently been standardized, it was recom- 
mended to put more emphasis on prevalidation before starting formal valida- 
tion. This was in particular addressed by an ECVAM Task Force on prevalida- 
tion which has defined the role of prevalidation in the development, validation 
and acceptance of altemative methods (Curren et al., 1995). According to this 
new concept during prevalidation a standard protocol has to be worked out for 
a newly developed test which then has to be independently tested and approved 
by another laboratory before the assay should undergo a formal validation 
under b1ind conditions in several laboratories.  
Validation trials of in vitro alternatives to the Draize rabbit's eye test  
German study on the HET -CAM test and a cytotoxicity assay  
 
 Since 1988 in Germany a national validation study on two altematives to 
the Draize eye test has been conducted under blind conditions in 14 labora- 
tories. It was funded by the German Department of Education and Research 
(BMBF) and coordinated by ZEBET. To identify severely eye irritating chemi- 
cals (EU labelling R-41) an empirically developed scoring system was used 
both for the HET -CAM assay and the IC-50 value for the 3T3 cel1 
cytotoxicity test. As previously reported for a total of 200 test chemicals, 
cytotoxicity data did not sufficiently correlate with in vivo Draize eye test data 
and the sensitiv- ity and specificity of the HET -CAM assay were not 
coI:tvincing for identifying severely eye irritating chemicals (Spielmann et al., 
1991, 1993). Toxicologi- cal endpoints and scoring systems of the HET -CAM 
assay had been derived empirically. It was, therefore, investigated if modem 
biostatistical methods facilitate to better identify the most predictive endpoints 
and/or scores of this particular assay, as e.g discriminant analysis, and to 
calculate in vitro/in vivo correlations, e.g. complex regression methods.  
 
 Discriminant analysis revealed that among the 9 endpoints of the HET - 
CAM assay, coagulation was the only acceptable endpoint for identifying 
severely irritating chemicals (R-4l). The data also allowed to develop an in 
vitro testing strategy for identifying severely eye irritating chemicals (R-41), 
which is based on combining coagulation data from the HET -CAM assay with 
cytotoxicity data and which provides an acceptable sensitivity, predictivity and 
percentage of false positive results (Spielmann et al., 1995). Complex re- 
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gression methods gave a better description of the in vitro/in vivo correlation 
between the different endpoints evaluated in the Draize eye test in vivo than the 
usual simple linear models.  
 
EU study validation ofthe BCOP assay  
 
 In 1991/93 the DG XI of the EU funded a blind validation trial of the 
bovine coreneal opacity and permeability (BCOP) assay in 13 European lab- 
oratories including ZEBET. In the study the predictive value of the BCOP 
assay was tested for classifying industrial chernicals according EU classifica- 
tion as eye irritants (R 36) and severe eye irritants (R 41). All chernicals were 
tested in vivo in a contract laboratory in the Draize eye test and assesed using 
the MMAS score. Comparison of in vivo and in vitro data revealed that the 
BCOP assay predicted correctly whether a compound is irritating or nonir- 
ritating for 44 of the 52 chernicals (85%) and that sensitivity and specificity of 
the assay were greater than 84% (Gautheron, 1994). Therefore, the BCOP 
proved to be quite useful for screening chemicals for their ocular irritation 
potential.  
 
Worldwide ECIHome Office validation study  
 
 In 1992 the DG XI of the EU in cooperation with the British Home Office 
has initiated an international validation study on the most promising 
alternatives to the Draize eye test. The principal goal of the study is to provide 
scientifically credible data for proposing to regulatory authorities that one or 
more non-whole-animal methods should be adopted as a replacement for the 
Draize rabbit eye irritation test, and that four target steps related to this goal 
were to determine whether or not the data obtained in the study indicate that it 
would be possible:  
 1) to replace the Draize eye test for identifying severely irritating mate- 
rials or  
 2) to replace the Draize eye test for identifying severely irritating materials  
  belonging to specific chemical classes or  
 3) to replace the Draize eye test completely (i.e. to identify all levels of 
irritancy of materials without regard to their chemical class) or  
 4) to replace the Draize eye test for identifying all levels of irritancy of 
materials belonging to specific chemical classes.  
 
 The EC/HO validation exercise is covering 9 non-animal methods estab- 
lished in laboratories of the European chemical industry including organotypic 
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models and cellular and physicochemical assays. Each test was performed in at 
least 4 different laboratories in Europe, Japan and the USA and 60 coded 
chemicals were testes under blind conditions. The study was carried out ac- 
cording to the recommendation of the CAAT /ERGATT workshop on the val- 
idation of toxicity test procedures (Balls et al. 1990). 60 test chemicals with 
high quality in vivo data covering the whole range of eye irritation between 
MMAS 0 and 110 had been carefully selected by experts of ECETOC, the 
European chemical manufacturer's association. Coding and shipping of test 
chemicals as well as handling and analysis of the data were carried out in- 
dependently by a contract laboratory as suggested by the first joint US and 
European workshop on validation (Balls et al., 1990). Due to their experience 
in validation studies both ECVAM and ZEBET were involved in managing this 
project. The experiments of this validation trial were finished early in 1994 and 
the results will be published in 1995. Preliminary evaluation of the results of 
this study suggests that even the best in vitro assays presently available hold 
promise only for testing surfactants but not for a more wide spectrum of 
chemicals.  
 
COLIPA validation study ofsurfactants  
  
 COLIPA, the European cosmetic, toiletry and perfumery association, has in 
1994 started a validation study of in vitro assays. Taking into account both the 
interest of COLIPA member companies and the preliminary evalidation of the 
outcome of the EC/HO Draize eye test alternaties validation trial, this study is 
limited to surfactants as far as test chemicals are concerned. The COLIPA 
surfactants validation trial is carried out under blind conditions and follows the 
general recommendations of the ECVAM Workshop on validation (Balls et al., 
1995). Participants include cosmetic companies from Europe, Japan and the 
USA. More information about the study has not yet been released and results 
are expected to be published in 1996.  
 
Validation of in vitro Phototoxicity Tests  
 
 Acute photoirritation testing is an area, in which in vitro models using 
human or animal tissue seem to be more promising than the animal models 
developed so far. In 1992 the DG XI of the EU and COLIPA have started a 
joint validation project of acute in vitro phototoxicity tests, which was initi- 
ated and managed by ZEBET with 8 laboratories participating in 4 European 
countries. The goal of the project was to determine if currently selected in vitro 
methods are capable of properly predicting the photo-irritation potential to 
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humans of chemicals applied via the systemic route or topically to the skin. 
The results are summarised in Table 1.  
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 Subsequent to the successful first phase of the study in which the most 
promising in vitro tests were identified (Liebsch et al., 1994) in 1994 a blind 
trial was started with 10 laboratories participating in 7 countries in Europe and 
the USA. The study was carried out according to recommendations of the 1990 
workshop on validation with independent management, coding and shipping of 
test chemicals and of data handling and analysis. In this study the newly 
developed 3T3 cell NRU phototoxicity assay (Spielmann et al., 1994) and the 
red blood cell phototoxicity assay (Table 1) are core tests to be carried out in 
most of the participating laboratories. In addition, six in vitro photoirritation 
tests, which have not yet proved interlaboratory reproducibility, are tested only 
in a few laboratories. These assays are covering the following endpoints of 
acute phototoxicity: histidine oxidation, cytotoxicity in human keratinocytes, 
complement activation and protein binding, which may indicate photoallergy 
potential. In addition, two commercially developed assays are included, which 
can handle insoluble materials, the Skin2-TM ZK1350 and the SolatexTM PI 
assay. Results will be available by the end of 1995.  
 
Prevalidation Study on In Vitro Skin Corrosivity Testing  
 
 In 1993/94 ZEBET participated in a European validation trial on in vitro 
skin corrosivity assays (Botham et al., 1995). In 7 laboratories 50 test 
chemicals were tested in 3 in vitro assays, the TER assay (transcutaneous 
electrical resistance) using rat skin, and two commercial assays, the Skin2- TM 
in vitro skin corrosion test using a three-dimensional human skin model, and 
the CorrositexTM assay, which is a biobarrier model combined with a chemical 
detection system.  
 The aims of the prevalidation study were  
1) to evaluate the relative performance of the three assays in correctly pre- 
dicting defined corrosive and non-corrosive test chemicals,  
2) to assess the interlaboratory variability of the methods, and 
3) to assess the status of standardization of the methods.  
 
This study showed that all of the tests are well established and can all be 
transferred from one laboratory to another. However, before entering formal 
validation each test requires optimization of the corrent testing procedure. To 
speed up validation and acceptance of in vitro skin corrosivity assays ECVAM 
has advertised to fund participation of European laboratories in the formal 
validation trial under blind conditons.  
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National Validation Study in Germany of a Fish Cell Test to Assess 
Waste Water Toxicity  
 
 A national validation trial on a fish cell assay. was initiated by ZEBET in 
1992 to replace a fish test which is used for regulatory purposes in Germany. 
After three laboratories established a standard test protocol in 1993/94, a blind 
trial was funded by the German BMBF in 1994/95 with 9 laboratories from 
industry and government institutions participating and 200 waste water 
samples to be tested. ZEBET has tried to ensure that this study is carried out 
according to the recommendations the the ECVAM Workshop on validation 
(Balls et al., 1995). Coding and shipment of test chernicals was perforrned 
independently. Data analysis and evaluation will be carried out at ZEBET 
which is not participating experimentally otherwise in the study. Results will 
be reported early in 1996.  
 
Biostatistics of Validation Studies  
 
 Since 1992 ZEBET is participating in a nationa1 project on developing 
biometrical methods for evaluating toxicological in vitro tests which is spon- 
sored by the German BMBF. This research activity is aimed at using modern 
biostatistical methods to identify predictive in vitro endpoints during the stage 
of test development. Another goal of the project is to provide guidelines for 
recording, handling and analysis of in vitro data according to GLP standards. It 
is furthermore attempted in this projects to standardise statistical methods for 
measuring reproducibility of in vitro test methods and also for calculating in 
vitro/in vivo correlations (Spielmann et al., 1995). In 1994 ECVAM estab- 
lished a Task Force on biostatistics which will provide guidance and support as 
far as biostatistics are essential in planning and evaluating validation studies.  
 
CONCLUSIONS  
 
 The validation of in vitro toxicity test procedures is a new field in exper- 
imental toxicology. Since integration of such methods into regulatory testing 
has a very high political priority in Europe, the EU has during the past five 
years increased funding of validation studies and established the EuropeaI1 
Validation Centre ECVAM in 1992. To promote the acceptance of non-animal 
methods in toxicology the EU has in 1994 accepted an amendment the EU 
cosmetics directive according to which animals testing for the development of 
new cosmetics will be banned within the EU after January 1, 1998. This par- 
ticular regulation has stimulated cooperation between the cosmetics industry in 
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Europe represented by COLIPA and of govemment agencies which are en- 
gaged in funding, development and validation of non-animal testing methods, 
as e.g. ECVAM and ZEBET. The joint efforts have lead to establishing high 
standard in vitro toxicology laboratories in the most important countries of 
Europe which are very actively participating in intemational validation studies 
within European and beyond. Taking into account both the cosmetics directive 
and the areas in toxicology where replacement of animal tests seems feasable 
in the short run, most of the validation studies have focused on local irritancy 
tests on skin and mucous membranes.  
 
 Due to restrictive legislation on the one hand and to govemment funding of 
research on the other hand Europe has taken the lead in this particular field of 
the biomedical sciences. After avoiding to get involved, Japan and the USA 
seem to follow now driven by both the damands of the consumers and 
legislation.  
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Toxicity of xenobiotics. Classification of toxins  
 
 Man is habitually exposed to a large variety of foreign substances (food 
additives, cosmetics, pollutants, chemicals, pharmaceuticals, etc) which are 
potential1y toxic and harmful to different organs and tissues. Among these, 
pharmaceuticals constitute a group of compounds developed for use by man 
and of particular relevance in the biomedical field, and their safety, therefore, 
should be clearly demonstrated.  
 
 Substances capable of producing cell damage are known as toxins. They 
are classified according to whether they exert their effects in all individuals, in 
a dose-dependent and hence "predictable" manner (intrinsic toxins), or do so 
only in some individuals commonly after several contacts, in a non-dose 
dependent, and therefore "unpredictable" way (idiosyncratic toxins). In the 
former case, toxins may act directly on cellular systems (active toxins) or after 
biotransformation by hepatocytes (latent toxins). In the latter case, the toxicity 
may be the consequence of an uncommon metabolism of the drug (metabolic 
idiosincrasy) or be mediated by the immune system after repeated previous 
contacts (sensitization).  
Molecular mechanisms involved in the toxicity of xenobiotics  
  
 The molecular mechanisms involved in the toxicity of xenobiotics are of 
major concern to toxicologists. While it is quite easy to determine the in vivo 
doses that produce toxicity, it is more difficult to find out why cel1 death 
occurs or what event leads to an irreversible change in the living system that in the 
end is responsible for the cell death.  
 
 Some xenobiotics are electrophilic in nature, and others are biotrans- 
formed by the liver or other tissues to highly reactive metabolites which are
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 generally more toxic than the parent compound. This activation process is the 
key to many toxic phenomena (1). Although a biotransformation sequence 
generally parallels a detoxification process, there are many cases in which the 
metabolites formed after Phase I reactions can cause deleterious effects to cells. 
For instance, some metabolites are potent electrophiles or carbon-centered 
radicals capable of reacting with nucleophiles able to covalently bind to 
macromolecules (proteins, DNA), or initiate radical-chain reactions (lipid 
peroxidation), or cause oxidative stress by catalyzing the reduction of oxygen 
by NADPH. Against these potential hazards, hepatocytes have their own de- 
fence mechanisms (GSH, DNA-repair, suicide inactivation etc.). Ultimately, it 
is the balance between bioactivation and detoxification which determines 
whether a reactive metabolite will elicit a toxic effect or not.  
The need of in vitro methods in the development  
of drugs and chemicals  
 
 Testing for the toxicity of new drugs is a basic aspect of the research carried out 
during their development and now forms part of the routine battery of in vivo assays. 
However, the use of animals is expensive, meets increasing social opposition, and 
cannot be applied to many different compounds at the same time.  
  
 These three factors -1) the need for rapid, cheap methods for screening toxicity at 
a very early stages of development, 2) the demanded reduction in the number of 
animals used, and 3) the possibility of experimenting with human-derived cells- have 
led to a growing interest in precise models that could be used as alternatives to 
anticipate the potential toxicity of drugs and chemicals in man.  
 
 An in vitro method offers a series of advantages. I t can be used in the early stages 
of drug development, and only a small amount of the compound is needed for the 
assays; it drastically reduces the use of laboratory animals; and, as in the case of 
primary cultured cells from the organs (liver, kidney, lung, skin, nervous system, etc), 
it can provide direct information about the potential effects on the target organ.  
The  in vitro evaluation of toxicity  
 
 The quality and specificity of the data generated by in vitro models depends on 
several factors (2):  
 1) The selection of the biological system.  
 2) The choice of appropriate parameters for evaluating toxicity in vitro.  
 3) Correct designing of the experiments so that the results obtained in vitro  
are predictive of those in vivo. In other words, how should the in vitro 
data be interpreted to anticipate the potential in vivo effects?  
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The choice of an appropriate biological system  
 
 We may have different in vitro conditions for handling cells outside the 
organism, which can be chosen according with the object and experimental 
design of our research. Primary cultures of cells derived from organs and 
tissues express most of the specialized functions typical of the tissue or organ 
of origin. Cells are obtained from the tissues by enzymatic or mechanical 
means, have a limited life-span in culture and are proliferating (lung, 
keratinocytes, kidney cells, etc) or non-proliferating (hepatocytes) cultures. 
These differentiated cells are the model of choice for organo-specific toxicity 
studies. An important factor in cytotoxicity assessment is the relationship 
between the cell type studied in vitro and the target organ in vivo.  
 
 Established cell lines derive from primary cultures of diploid cell lines by 
transformation processes which are either spontaneous or induced by viruses, 
chemical or physical agents, or they derive from tumoral tissues. Although a 
few established cell lines are able to express specialized functions of the tissue 
or organ of origin, most of them are undifferentiated. Established cell lines are 
used for basal cytotoxicity studies In vitro assays using human-derived cells.  
 
 Research with humans has important ethicallimitations and the cellular 
animal models do not always reproduce the behaviour of.human cells. This is 
particularly important when the metabolic profile of a new drug is investigated. 
Therefore the possibility of experimenting with human-derived cells has made 
the search for in vitro methods able to detect the potential toxicity of drugs  
to man very attractive.  
 
The choice of appropriate parameters for evaluating 
 toxic effect in vitro  
 
 When selecting end-point parameters for toxicity two questions have to be 
considered: What kind of information do these parameters provide?; Are all 
parameters equally relevant? .  
 
 Cytotoxicity end-point parameters (cell viability, cell survival, enzyme 
leakage etc.) represent a first step torward evaluating toxicity, but evaluation of 
these parameters alone may leave out of consideration xenobiotics that impair 
target cell function without causing cell death. This may not be critical for the 
target cell itself but of toxicological significance for the whole organism. 
Experiments on cytotoxicity are designed to determine the maximal non toxic 
concentration (MNTC) of a drug, i.e. the highest concentration compatible with 
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cell survival. This is roughly estimated for each parameter as the concentration 
causing only 10% of the maximal cytotoxic effect.  
 
 At sub-cytotoxic concentrations it is possible to design experiments to 
examine the interferences that a given xenobiotic can cause in the specialized 
functions of a target cell in culture (Target organ toxicity). Concentrations to 
which cells are exposed for cell metabolism studies should not cause 
perceptible cell death.  
 
 The cytotoxic end point parameters give information about the maximum 
drug concentration compatible with cell survival. The metabolic parameters 
provide direct information about the extent to which a cell's specific functions 
are altered. In vitro tests that give an indication of impaired cellular functions 
specific to one class of cells (hepatocytes, neurons, myocytes, etc.) make a 
clear contribution to the risk assessment evaluation. Toxicity data are 
expressed as Icl0 and IC50 (concentration causing l0 or 50% inhibitory effect 
of the evaluated parameter).  
Studies of drug metabolism in vitro  
 
 Detailed knowledge of the metabolism of drugs is essential as early as 
possible in the research and development process, for two main reasons: 1) the 
metabolism of drugs generally is the major determinant of their pharmacoki- 
netics, interindividual variability and interactions with other compounds, and 
2) differences in metabolism are often responsible for difficulties in extrapo- 
lating from toxicological test species to humans.  
 
 Biotransformation of xenobiotics is an evolutionary acquisition of higher 
organisms that enables them to eliminate lipophilic substances that otherwise 
might accumulate in tissues, thereby causing toxic effects. This process oc- 
curs at different levels in the organism, but the liver is the most active organ in 
metabolizing foreign compounds. Biotransformation of xenobiotics involves 
chemical modification of the compounds. Most of such processes are redox 
processes catalyzed by a family of hemoproteins, namely, cytochrome P450- 
dependent monooxygenases(Phase I reactions). The result is a new metabolite 
or metabolites that usually are more polar and reactive and are further con- 
jugated by hepatocytes with endogenous molecules (Phase II reactions), thus 
facilitating the elimination of lipophilic substances. human liver.  
 
 The basic reason for using hepatocytes for drug metabolism studies is that 
these cells retain in culture their characteristic in vivo drug-metabolizing 
activities and the metabolism of a particular xenobiotic by cultured cells is 
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comparable to that found in vivo (3). Although gradually decreasing in culture, 
these activities are expressed and can be induced by drugs in primary cultured 
cells for several days. Therefore, the most important application of this in vitro 
system is in of anticipating the hepatic metabolic profile of a compound before 
using it in man. For metabolism studies, drugs are incubated with intact human 
hepatocytes, and after incubation unaltered drug and the metabolites formed 
can be recovered and identified by analytical methods.  
 
 The use of human hepatocytes to anticipate the metabolic profile of a new 
drug in man is of particular relevance. On the other hand, by comparing the 
concentration-toxicity curves of the compound in fully competent primary 
cultured hepatocytes and in non-hepatic cells (i.e. fibroblasts) it can be investi- 
gated whether bioactivation of a drug is required for cellular damage to occur . 
In addition, the large biotransformation capability of the liver also makes it one 
of the most important target organ for drug toxicity.  
Interpretation of in vitro data  
  
 A key point in vitro research is the value of experimental data for an- 
ticipating in vivo effects. Although extrapolation of the in vitro experimental 
results to man is the ultimate goal, it is difficult to search. Several factors are 
relevant when it comes to interpretating in vitro data in relation to the most 
probable in vivo effects (2):  
 1)  The sensitivity of the in vitro model used.  
 2) The relevance of the biochemical function affected and, in close 
conection with this, the reversibility of the effect.  
 3)  The pharmacokinetics of the drug in vivo.  
 
 The first point refers to the ability of cells to detect potential in vivo toxins. 
Although cells are sensitive to toxins at concentrations equal or even lower 
than those reported to be toxic in vivo, the model may lack sensitivity for drugs 
that require extensive biotransformation or prolonged exposures to exert their 
toxic effect.  
  
 A second relevant aspect of data interpretation is the reversibility of the 
toxic effects. A compound may alter one or more relevant cellular hepatic 
functions. However, their effect might be transient and when the drugs are 
withdrawn from the culture medium, cells recovery their functionality.  
 
A final point, in relation to the in vivo relevance of in vitro experimental data is 
the pharmacokinetic of the drug. Blood concentration of a drug changes 
characteristically with time. Whenever possible, this fact should be taken into 
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account in the experimental design in vitro. It is complex to reproduce in vitro 
the changes in the concentration of a drug as they occur in vivo. A simplified 
approach to compare in vitro and in vivo situation is to expose cells to an AUC 
(area under the concentration/time curve) equivalent to what is known to occur 
in vivo (experimentally determined or estimated by PBPK models).  
 
 A simple way to rank the relative potential toxicity of a drug within a 
homologous series of compounds is to compare the plasmatic concentration of 
the drug in vivo with the concentration causing toxic effects in vitro. The 
toxicity risk (TR) is thus defined as the quotient of both magnitudes. The larger 
the values of TR are (closer to 1 or even greater), the greater the toxicity risk 
will be for a given drug. It can be reasonably assumed that if a drug reaches a 
plasmatic concentration at a concentration that is toxic in vitro and stays there 
for a period of time that is also conducive to toxicity in vitro, it is highly 
probable that this compound will show toxic effects in vivo.  
 
Toxicological information that an in vitro test can 
 provide on a new drug  
 
 In vitro research can provide several types of information:  
 
 1)  Drug analogs can be ranked on the basis oftheir increasing molar 
toxicity in vitro.  
 2)  The major metabolic alteration in the target cell caused by a drug can be 
foreseen.  
 3)  An upper limit of the AUC curve (concentration x time) beyond which 
a drug is likely to have toxic effects in vivo can be estimated.  
 4) The molecular mechanism involved in the toxicological effect can be 
investigated.  
 5)  Prediction of in vivo biokinetics (membrane transport, protein binding, 
mathematical modelling etc.).  
 6) The evaluation of drug-drug interactions.  
 7) The metabolic profile of a new compound after biotransformation by 
primary cultured hepatocytes can be predicted. The use of human 
hepatocytes to anticipate the metabolic profile of a new drug in man is 
of particular relevance.  
 8)  The animal species that most closely represent the metabolic profile of 
a given drug in humans can be identified.  
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General applications of the in vitro methods in drug  
and chemical toxicology  
 
 The different areas of application of in vitro methods for evaluating the 
potential risk of toxicity of drugs and chemicals in man are:  
 
1) Classification and labeling of chemicals according to their toxic 
potential.  
 
2) Evaluation of the suitability and toxicity of biomaterials used in odon-
tology, traumatology, etc.  
 
 3)  Local irritation tests (ocular and cutaneous) which replace the 
conventional in vivo tests in rabbit (Draize test).  
 
 4) Detection of inhalable contaminants ( cigarette smoke, volatile industrial 
residues, etc) that act directly on the lung and may cause important 
damage to cells.  
 
 5) Systemic toxicity, evaluating the toxic effects on different target organs, 
helping us to predict acute toxicity of xenobiotics to man.  
 
 6) Detection of chemical mutagens by evaluating their potential carcino- 
genic activity on cells.  
 
 7) Phototoxicity of drugs evaluated on cellular models.  
 
General comments on the use of in vitro methods in  
toxicological research  
 
 In vitro cellular models have proved to be extremely useful in some areas 
of toxicology research. The organ-specific or basal acute toxic effects of a 
particular compound can be assessed with the combination of metabolically 
competent cells from the target organ in parallel with non-differentiated cell 
lines. The species-specific effect of a chemical can also be easily evaluated by 
using in vitro cellular systems from different species. Another incentive for 
using in vitro cytotoxicity assays is that they can reduce unethical and uneco- 
nomical animal models for toxicity testing of chemicals, such as new drugs.  
 
 Alternative procedures for assessing the acute toxicity of chemicals have 
proliferated in the recent years, but widespread acceptance and use of these 
assays have been hampered by their lack of validation. Validation is the crucial 
process which must take place between test development and acceptance by the 
general scientific and industrial communities, and refers to a process designed 
to evaluate the reliability and relevance of in vitro tests. The importance of the 
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relationship between relevance and reliability is necessarily linked to the 
concept of validation. For instance, a test which demonstrates favorable results 
for a large number of chemicals can be assumed to be fairly reliable. In 
contrast, a very reliable method may not be useful if it has not demonstrated 
some relevance to the in vivo situation.  
 
Concluding remarks  
  
 When a new pharmaceutical is being developed, its possible hepatotoxic 
effects are examined as a part of the normal battery of assays to which com- 
pound is routinely subjected. Present demands for safer medicines contrast 
with the increasing opposition to the massive use of laboratory animals needed 
to evaluate toxicity. This situation has led to a growing interest in precise 
models that could be used as alternatives that can be used to predict possible 
toxicity and to reduce the use of animals for experimentation. In theory, an in 
vitro method offers a series of advantages: it can be used in the early stages of 
developing the drug; only a small amount of the compound is needed for the 
assays; it drastically reduces the use of laboratory animals; and, in some cases 
like that of human hepatocytes, it provides a very specific and direct 
information about potential effects on the human liver .  
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 The science of toxicology defines the interaction between chemical and/or 
physical agents and the consequences of alterations to living tissues, cells, and 
intact organisms. Toxicology also provides a way to delineate and understand 
the risk to humans and animals from exposure, either intentional or acciden- 
tal, and to prevent the consequences of that biological-agent interaction. This 
presentation will explore the need for mechanistically based tests, discuss some 
of the issues one has to consider in developing in vitro methods and present an 
approach to validation of in vitro methods.  
 
Correlation Versus Mechanism  
 
 The early stages of in vitro toxicology have been focused on descriptive 
and correlative approaches to methodology development. Much of the deve- 
lopment has been focused on skin and eye and general toxicity. However, it is 
becoming increasingly apparent that for the science to advance we must 
develop mechanistic understandings of the relationships between xenobiotics 
and biological systems.  
 
 Correlative test generally lead to trivial understandings and do not provide 
true predictive knowledge. This is not to say that correlative tests are without 
merit. These assays have merit and are useful as screens, adjuncts and in 
attempts to make decisions about chemicals within a class. At this point in the 
development of the science, correlative tests are being used and used 
appropriately.  
 
 Mechanistically based tests, however, will provide us with true under- 
standing of toxic processes and thus, the ability to predict the consequences of 
exposure to chemical agents. When we develop mechanistically-based tests and 
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multiple endpoints, we will be able to establish acceptable criteria for replacement 
methodology. Further, a focus on mechanistically-based test cre- ates the 
understanding that a single test will rarely replace an in vivo test (Frazier, 1990). 
As one develops an understanding of mechanism, one recog- nizes that batteries of 
tests will be required. Mechanistically-based tests, by definition, will yield false 
negative results in any one test, but a battery of test will provide true positives.  
 
Potential Mechanisms of Toxicity  
 
 Goldberg and Silber (1992) identified several potential mechanisms of general 
toxicity. To fully utilize in vitro toxicology in risk assessment, methods must be 
developed to measure these as well as yet to be defined mechanisms. This list 
(Table 1) is not intended to be comprehensive but it is a starting point for a broader 
discussion. One goal of these discussions will be to more sharply define additional 
mechanisms and tests to measure these mechanisms.  
 
TABLE 1 
 
Selected Mechanisms Associated With Toxicity 
 
• Autophagy-Protein Degradation  
• Calcium-Mediated  
• Cell-Cell Communication  
• Cellular Pathways 
• Cytoskeleton  
• DNA Repair  
• Free Radicals  
• Membrane Effects  
• Programmed Cell Deaths  
• Receptor-Mediated Mechanisms  
 
 
Neurotoxicity-An Example  
 
 One need is to have multiple endpoints that measure different aspects of the 
range of biological activity.  
TABLE 2 
Systems End Point Measures 
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Dissociated Tissue (synaptic endings)
  
Cell Cultures 
(Neuronal, glia neuroblastoma)  
 
 
 
Brain Slices  
Invertebrates  
Vertebrates  
Human  
 
 
Functional Consequences  
 
Enzymes (rate, amount) 
Substrates/metabolites 
Neurotransmitters 
(level, released) 
 
Receptors 
Kinetics  
Physiology (e.g. Patch Clamp) 
Biochemistry  
Pathology  
Behavior  
Myelin 
 
 Table 2 describes potential systems to measure neurobiological functions.   The 
column on the right provides a list of endpoint measures.  Clearly, not all functions 
can be measured in all systems.  Nonetheless,  this approach permits one to examine 
possible options.   
 
 At a recent meeting of the Office of Technology Assessmet -U.S. Congress 
(OTA, April 24, 1995) participants were requested to examine the current "gold 
standard" assay and assess whether or not it met our needs and also to look at short 
term tests that might succeed as replacement and/or comple- mentary methods. 
Much of the current focus on in vitro tests for regulatory consideration are in the 
areas of cytotoxicity, skin, and eye irritation. In many other systems in vitro assays 
are used mainly to create a fuller understanding of biological processes and are 
used only in the last stages of compound evaluation. This is an area that requires 
considerable development as it offers many opportunities to decrease animal use 
and at the same time increase our understanding of the biological consequences of 
chemical exposure.  
 
In the case of neurotoxicity, it appears that whole animal assays examine 
functional (neurophysiological and behavioral) and structural (pathology) 
components. It is not until Tier 4 (the last stage of evaluation) that in vitro assays  
are  included.  Clearly, one of  the  future  goals of  our work  will be to provide 
methods and approaches that will lead to in vitro assays being incor- porated in 
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Tier 1 (the earliest stage of evaluation), so that animal use will be decreased and 
more rapid evaluation of toxicity /safety becomes possible.  
 
 In the development of drugs, in vitro approaches are used very early in the 
development of new compounds, but this should not be confused with testing 
practice to meet environmental laws and evaluate safety.  
 
 We are not yet taking full advantage of human tissue for studies of the nervous 
system. This is an area just beginning to develop, while in areas like skin toxicity 
studies the use of human cells is routine and significant advances have been made.  
 
 I would like to raise 3 issues for discussion. First, have we catalogued the 
regulations and examined where in vitro test are being used and/or developed and 
where attention needs to be focused? Secondly, how do we encourage the 
incorporation of in vitro approaches into de earliest stages of toxicity evalua- tion? 
, and finally, what is necessary to encourage the use of human cells?  
 
VALIDATION  
 
 This section is taken almost verbatim from A Modular Approach to Va- 
lidation - A Work In Progress (1).  
 
Background And Significance  
 
 The Validation Program of CAAT was implemented in 1989 following a 
recommendation of the CAAT Advisory Board at its 1988 retreat. CAAT is a likely 
core for validation activities given its mission and its unique and independent role 
as a liaison organization between academia, industry and government. The program 
was initiated with the establishment of the CAAT Committee on Validation and 
Technology Transfer, co-chaired by Drs. Emil Pfitzer, of Hoffman-LaRoche Inc. 
and Robert Sacla, of Exxon Corp. At its inception, the overall objective of the 
committee was to catalyze the transfer of altemative testing technology from the 
research laboratory to practical ap- plication. The committee was charged with 
developing a framework to assess existing programs, coordinate future activities, 
establish a scientific structure for validation, and maintain strong links with 
regulatory, academic and indus- trial institutions (2).  
 
 Coincident with the formation of the Validation Committee, Dr. John Frazier, 
former Associate Director of CAAT, produced the seminal document on validation. 
Dr. Frazier was invited by the Secretariat of the Organisation of Economic 
Cooperation and Development (OECD) to write this document to establish criteria 
for validation was published by the OECD in 1990 (3). This document defined 
validation as the process by which the credibility (re- productibility and reliability) 
of a candidate test is established for a specific purpose. Frazier also identified three 
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stages in the validation process (intra- laboratory assessment, interlaboratory 
assessment and test database develop- ment) and described two approaches to the 
development and use of in vitro methods for toxicity testing-the empirical 
[correlative] and the mechanistic. He concluded that for in vitro tests to be used as 
a total replacement for whole animals, they must be mechanistically based. 
Empirically based tests may be sufficient for screening purposes. The need for 
mechanistically based validated alternatives has been strongly debated, but was 
emphatically echoed in a 1992 ATLA editorial (4).  
 
 As a result of the publication of the OECD document, members of the 
European Research Group for Alternatives in Toxicity Testing (ERGATT) or- 
ganized a joint workshop with CAAT. The purpose was to conduct extensive 
discussions on all matters related to the validation of toxicity test procedures and 
produce an authoritative report, published in a peer .review journal for the guidance 
of researchers, regulators and others. The results of this workshop ap- peared as a 
multiauthored article in the journal ATLA (5) and simultaneously printed as CAAT 
Technical Report No.3.  
 
 In spite of the importance of the publication of these documents, some 
observers maintained that they did not provide a design or framework for a 
validation methodology. Part of the difficulty in establishing such a framework for 
the validation process is a function of the different needs of individual industries 
and government regulators. Thus the ensuing challenge of the CAAT Validation 
Committee became one of defining a framework for validation that both 
established rigorous criteria and yet could be used by multiple industries. After a 
few years of meetings and lively debate, the Validation Committee developed its 
framework for the validation and implementation of in vitro toxicity tests and it 
was simultaneously published in four different journals in 1993 (6).  
 
 The framework document identifies the administrative requirements to 
organize, coordinate and evaluate validation activities. It proposes the cre- ation of 
a Scientific Advisory Board of experts in the various aspects and end- points of 
toxicity testing to provide oversight of validation resources, expertise and review of 
design/conduct of validation programs. Validation resources, in the form of core 
facilities, would also be established. These resources include chemical banks, data 
banks, cell and tissue banks and reference laboratories. Most importantly, the 
document stresses that peer review and publication of scientifically evaluated tests 
are integral to the process. This document was the first to present criteria for 
implementation of validation methods.  
 
 While these activities were taking place in the USA, the European Union (EU) 
established the European Center for the Validation of Alternative Me- thods 
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(ECVAM) to direct and coordinate validation activities in Europe. With the 
passage of the EC Cosmetics Directive baning the sale of animal tested 
cosmetics/cosmetic ingredients after January 1998, European toxicologists and 
regulators need to validate non-animal tests for these products. While the NIH 
Revitalization Act of 1993 mandates the Institutes to develop replacement, 
reduction and refinement methodologies, there is no comparable government- 
funded center or organization in the US to direct parallel activities, although a 
multi-government agency was created in 1994 to develop criteria for validation.  
 
 Following the creation of an altematives laboratory at Rockefeller Uni- versity 
in 1980, and the formation of CAAT at Johns Hopkins University in 1981, there 
was general recognition that it would be necessary to develop a validation 
methodology for the assays that would be developed at these cen- ters. Many 
individual companies and trade associations instituted "validation" programs. 
However, it very quickly became apparent that these pilot studies failed to meet 
rigorous criteria and generally would not result in validation of any methodology. 
These pilot programs provided some useful data, but they were not substitutes for a 
validation methodology. All of these studies were simple in design and simple to 
understand and thus were quickly accepted in concept. Unfortunately, they were 
not and have not been acceptable due to the lack of scientific rigor. On the other 
hand, recent studies undertaken by industry have been excellent and have resulted 
in the industry accepting methodology for their own internal decisions.  
 
 With the development and publication of the framework for validation, a major 
hurdle has been overcome. However, what remains to be accomplished is the 
implementation of this framework. There is concern the most scien- tifically valid 
tests may not necessarily be the ones which become accepted. CAAT maintains 
that it is essential for methods to be evaluated using rigorous scientific criteria.  
 
First Principles  
 
 1) Definition: The process by which the credibility (reliability and repro-. 
ducibility) of a candidate test is established for a specific purpose.  
2) Framework: The study should be conducted according to preestablished 
guidelines. There are three distinct stages: test development, validation, and 
acceptance (Goldberg, A., Frazier, J., et al, (1993).  
 
MODULAR APPROACH  
 
  Several features of the validation effort should be noted:  
 
1) It is a modular study, with each module comprised of one chemical class 
paired with a single assay (and one endpoint).  
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 2)  A unique validation standard (for example, human concurrent studies) is 
identified for each module, i.e., each module has only one validation 
standard.  
 
 This approach limits each module to a single class of chemicals ( or a subclass 
within a class) which is linked to a predetermined validation standard.  
 
 
 
? CHEMICAL CLASS          ? VALIDATION STANDARD       ? ASSAY  
                   (Single Endpoint) 
            
 
VALIDATION IS THE USE OF A TEST FOR A SPECIFIC PURPOSE 
 
MEETS REQUIREMENTS OF THE CAAT FRAMEWORK FOR VALIDATION (REF. 
XENOBIOTICA, 1993, VOL. 23, NO.5, 563-572) 
 
 The third part of this module will be the Assay (System) and its endpoint 
measurement. Every module will have only one endpoint. Additional endpoints can 
be used but they will define a new module (1).  
 
 One of the most critical steps in this process is the need for optimized assay 
protocols and procedures. Rigorous standards must be developed. Issues that have 
not been adequately addressed are catalogued in this proceeding. (See papers by 
Spielmann and the paper by Balls of this proceeding).  
 
Summary  
 
 This presentation focused on the importance of knowledge of mechanisms of 
toxicity and the usefulness of alternatives in risk assessment. Questions raised 
during the presentation included the need for mechanistically-based tests, the 
incorporation of in vitro assays as a first approach in evaluating the safety of 
chemicals, therapeutic agents and other comercial products; the use of human 
ce11s and identifying regulatory requirements to encourage in vitro assays.  
 
 The presentation also provided an approach to validation that is based on 
fundamental principles and modeled after actual practice in other areas of 
methodology acceptance. It was recognized that the validation process is but one 
aspect of incorporation of in vitro approaches into safety evaluation and risk 
assessment.  
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THE DEVELOPMENT, VALIDATION AND ACCEPTANCE 
OF ALTERNATIVE METHODS 
 
Michael Balls 
European Centre for the Validation of Alternative Methods (ECVAM), JRC 
Environment Institute, 21020 Ispra (VA), Italy 
 
1. INTRODUCTION 
 
 The need for the orderly development and acceptance of alternative methods 
for use in biomedical research and testing, i.e. of methods which do not require 
the use of living vertebrate animals, results in both an opportunity and a 
challenge. In much of fundamental biomedical research, in vitro methods and 
computer models of various kinds are increasingly the methods of choice, since 
they offer opportunities for improving and exploiting our understanding of 
biological processes at the molecular and cellular levels. The validation of the 
new methods, i.e. the evaluation of their relevance and reliability for particular 
purposes, is conducted as a normal part of the conventional development of 
scientific methodology, i.e. through publication and peer review. 
 
 However, the non-animal methods also represent a challenge - to what extent 
can they be developed and introduced as replacements for the animal test 
procedures currently required by various laws as a basis for predicting the 
efficacy and/or safety of chemicals and products of various kinds, including 
medicines, vaccines, industrial chemicals, agrochemicals and cosmetics? In this 
case, validation must be a much more formal process, since the case put forward 
for accepting replacement alternative tests and testing strategies will have to be 
sufficiently convincing for the legislation, and the conservative attitudes of some 
scientists and administrators, to be changed. 
 
2. THE EUROPEAN UNION AND THE ROLE OF  
 ECVAM 
 
 Directive 86/609/EEC of the European Union [1] requires that “an 
experiment shall not be performed, if another scientifically satisfactory method 
of obtaining the result sought, not entailing the use of an animal, is reasonably 
and practicably available”. It also requires that, where an experiment on an 
animal has to be performed, for good scientific reasons, procedures “which use 
the minimum number of animals” and “which cause the least pain, suffering, 
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distress or lasting harm” must be used. 
  
 The belief is widely held that there is great scope for reducing the numbers of 
animals used in laboratories, not least through better experimental design and 
better analysis of the results produced [2], and this has led to a policy statement 
by the European Union that the Member States and the various industries 
concerned should seek a “50% reduction in the number of vertebrate animals 
used for experimental purposes” by the year 2000 [3]. Much more will be  heard 
of this target during the next few years. 
 
 At the same time, a great deal of effort has gone into refining laboratory 
animal procedures, so that the suffering caused is minimised. This has resulted 
from the implementation of Directive 86/609/EEC and various new national 
laws, and from the efforts of scientists themselves, not least from veterinarians 
specialising in laboratory animal science. 
 
 Meanwhile, the European Commission has established a European Centre for 
the Validation of Alternative Methods (ECVAM), with the principal task of 
coordinating the validation of replacement alternative test methods at the 
European Union level [4]. ECVAM has recently been discussing with its 
Scientific Advisory Committee the criteria for use in determining ECVAM’s 
priorities, and the following criteria for selecting priority areas have emerged: 
 1) The numbers of animals used. 
 2) The amounts of suffering caused to them. 
 3) The degree of public and political concern. 
 4) The needs of science and industry. 
5) The availability of potential replacement methods. 
 
6) The availability of standard test materials (backed by scientific knowledge 
 of sufficiently high quality) for use in validation studies.   
7) The feasibility of achieving scientific and/or regulatory acceptance of the 
alternative method and replacement of the animal procedure. 
 
8) Access to the necessary expertise for managing and conducting validation 
studies. 
 The efficacy and safety testing of human and animal vaccines will be high on 
the priority list, as will tests for dermal irritation and corrosivity, dermal 
penetration, nephrotoxicity and neurotoxicity. Validation studies on ocular 
irritation and on phototoxicity are in progress. 
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3. PROBLEMS WITH THE VALIDATION PROCESS 
 It is generally accepted that strict, but fair, criteria must be applied to the 
validation process itself, so that only methods which have been shown to be 
sufficiently relevant and reliable are proposed as replacements for the currently-
practised animal procedures. Much effort has been invested in thinking about 
how validation studies should be conducted, but a number of difficulties have 
arisen in practice, including the following: 
 1) The purpose of the proposed method is often ill-defined. 
2) Adequate test protocols are very difficult to obtain. 
 
3) Too much emphasis is often placed on reliability and not enough on 
relevance. 
 
 
4) Test materials of sufficient numbers and of sufficient variety, backed by 
good in vivo data, are not available. 
 
5) The question of how in vivo/in vitro comparisons should be conducted has 
not been adequately addressed. 
 
 6) Insufficient account is taken of the variability of both in vivo and in vitro 
data. 
 
7) Different methods are seen as competitors for acceptance for universal use, 
rather than as potential complementary components of a test battery. 
 
 8) Insufficient allowance is made for the advantages and disadvantages of 
particular tests and where their use would/would not be appropriate. 
 In view of these difficulties, and in the light of experience gained in recent 
years, an ECVAM workshop on practical aspects of validation was held early in 
1994. In the report of the workshop [5], great emphasis was placed on the need 
for a test to have been properly developed and a coherent case made for its entry 
into the validation process, before it is presented to a recognised validation 
authority (RVA) or other sponsors responsible for validation studies. This case 
should include a description of its basis and a definition of its scientific purpose, 
an explanation of the need for it in relation to the availability of other methods, 
and evidence of the intralaboratory reproducibility of its performance. 
 The ECVAM workshop report also recommended that more emphasis should 
be placed on a prevalidation step before formal validation, with the particular 
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aims of protocol optimisation and providing evidence of interlaboratory 
transferability. This recommendation has been taken up by an ECVAM Task 
Force on Prevalidation [6]. 
 
4. THE ECVAM PREVALIDATION SCHEME 
 The developers or other proponents of a new or modified method (designated 
Laboratory 1) would submit a proposal for a prevalidation study to an RVA, 
such as ECVAM, and/or to other potential sponsors, with the necessary 
supporting case. If the case presented were considered acceptable, a 
prevalidation study would include three main phases. 
 
4.1. Phase I: Protocol refinement 
 A laboratory with sufficient experience in the relevant area (designated 
Laboratory 2) would be contracted to modify the procedure proposed by 
Laboratory 1 into a workable, Good Laboratory Practice-compliant protocol 
or to confirm that such standardisation had already been carried out. Any 
necessary Standard Operating Procedures would also be produced, then the 
intralaboratory reproducibility of the protocol would be evaluated by using it 
to test a small number of appropriate test materials. 
 
4.2. Phase II: Protocol transfer 
 When the protocol had been refined to the satisfaction of Laboratory 2 and the 
overall managers of the prevalidation study, a third laboratory (designated 
Laboratory 3) would be contracted to establish the transferability of the protocol, 
by using the same test materials as were used in Phase I. Once all three 
laboratories and the managers of the study were in agreement that an optimised 
test protocol had been produced, discussions would take place about the aims and 
structure of Phase III. 
 
4.3. Phase III: Protocol performance 
 The precise aim of the protocol performance phase would be defined in 
consultation with the RVA and/or the other sponsors. In any case, a blind trial 
would be conducted, involving at least two laboratories and an appropriate 
number of test materials which had been independently selected, coded and 
distributed. Good in vivo data would need to be available for these test materials. 
The data obtained would be received and analysed by an independent statistician 
appointed for the study, who would prepare a report according to performance 
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criteria agreed in advance. Discussions on the outcome would then take place, 
involving all those who were concerned in any way with the study. 
 It is conceivable that some methods could be independently judged to be 
acceptable for incorporation into test guidelines as a result of a satisfactory 
outcome of the protocol performance stage. Normally, however, it is foreseen 
that a more formal, and more expensive, multi-laboratory study would be needed, 
perhaps including other methods. 
 
4.4. Subsequent action 
 Options for subsequent action would include the following: 
1) Recommending that no further work on the method be undertaken. 
 
2) Advising that further method development would be necessary, for 
example, in the light of the wider spectrum of materials that would 
need to be tested or the need for improvement of the prediction model. 
 
 3) Commissioning a formal validation study, perhaps in collaboration with 
one or more other RVAs or other appropriate sponsors. 
 
 4) Seeking an independent assessment with a view to the incorporation of 
the method into regulatory guidelines and regulatory practice. 
 
5. ACCEPTANCE 
 An ad hoc Interagency Coordinating Committee on the Validation of 
Alternative Methods (ICCVAM) has been set up in the USA, to establish 
uniform processes and consistent criteria wthin the Federal Government, that will 
lead to the scientific validation of new and revised test methods, and encourage 
the refinement and reduction of animal use in testing and, whenever scientifically 
feasible, its replacement by alternative methods. The role of ICCVAM is thus 
very similar to that of ECVAM in the European Union. 
 
 Meanwhile, the Organisation for Economic Cooperation and Development 
(OECD), which publishes guidelines on how toxicity tests on chemicals and 
certain other materials should be performed for regulatory purposes, has 
announced that a workshop on validation criteria for replacement alternative 
methods is being organised, as part of its Test Guidelines Programme and in 
collaboration with ECVAM and ICCVAM. 
 These moves are to be welcomed, since the international harmonisation of 
validation criteria should facilitate the acceptance of the new methods into 
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regulatory practice. However, as in the case of the harmonisation of test 
guidelines themselves, it is essential that harmonisation is combined with 
rationalisation and that all the necessary evaluations and recommendations are 
made in the open, so that they can be seen to be above board. 
 The word “method” is used to cover individual tests, test batteries and tier 
testing schemes, all of which need to be shown to be relevant and reliable for 
particular purposes, i.e. to be “validated”. Certain criteria need to be met before a 
method enters the validation process, and the following elements should be 
satisfactory: 
 1) A description of the basis of the method. 
 2) A definition of its scientific purpose. 
3) The case for its relevance. 
4) An explanation of the need for it in relation to type and extent of 
effects, levels of assessment, and availability of other methods. 
 5) Its proposed practical application. 
 6.) The availability of an optimised protocol with any necessary standard 
operating procedures. 
 7) A clear specification of endpoint, endpoint measurement, derivation 
and expression of results, and their interpretation, via a prediction 
model. 
 8) The inclusion of adequate controls. 
 9) A clear statement about its limitations. 
 10) Evidence of its intralaboratory reproducibility. 
 11) Evidence of its interlaboratory transferability. 
 In addition, the proper development and validation of methods both depend on 
a sufficient knowledge of the performance of the method with an adequate 
number of relevant test materials. The criteria involved here should include the 
adequancy of the following: 
 1) The relevance of the materials tested to the types of effects to be 
assessed and the range of expression of such effects. 
 2) The range of classes of materials and physical forms included. 
 3) The number of materials tested, both in total and in each sub-group. 
 4) Knowledge of in vivo effects, based on studies of sufficiently high 
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quality and involving publicly-available data. 
 Criteria for judging the quality and acceptability of validation studies 
themselves are also needed, and should include: 
 1. Clarity of defined goals. 
 2. Quality of overall design. 
 3. Independence of management. 
 4. Independence of selection, coding and distribution of test materials. 
 5. Independence of data collection and analysis. 
 6. Number and properties of test materials studied. 
 7. Quality of interpretation of results. 
 8. Performance of methods in relation to goals of the study. 
 9. Reporting of outcome in the peer-review literature. 
 10. Availability of raw data. 
 11. Independence of assessment of outcome. 
 
6. CONCLUSIONS 
 These criteria for judging the readiness of methods for validation, the 
suitability of the test materials used in validation studies, and the outcome of 
validation studies themselves, while essential, must be applied rationally, 
realistically and fairly. Once they have been established and agreed, the criteria 
for evaluating the outcome of a validation study must be applied, not only to 
replacement alternative (i.e. non-animal) methods, but also to proposals for new 
or modified animal test guidelines. At present, there is a widespread feeling that 
it would be much easier to get a new or modified animal test accepted at the 
OECD level than to have a current animal test guideline replaced by an 
alternative method not involving any animal procedures. Such a situation could 
not be tolerated, and, if it was found to be the case, immediate action would be 
necessary, not to lower the standards for accepting replacement alternative 
methods, but to raise the standards for accepting new or modified animal tests. 
 National and international laws for the protection of laboratory animals (such 
as the Animals [Scientific Procedures] Act 1986 and the EU Directive 
86/609/EEC) require that animals should not be used unless such use can be 
shown to be necessary for some justifiable purpose. How can the necessity of an 
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animal test be established, unless it can be clearly shown to be relevant and 
reliable for some worthwhile purpose? 
 
 In addition, these national and international laws require that non-animal 
methods be used whenever possible, so the emphasis must be changed in future 
from, “Why should this satisfactorily validated non-animal method be 
accepted?”, to “Why should the performance of the current animal test be 
allowed to continue, given the availability of relevant and reliable replacement 
alternative approaches which meet the agreed criteria and provide the 
information required?” 
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OVERALL REVIEW, SUMMARY AND CONCLUSIONS  
OF THE MEETING OF THE ICLAS/CSIC WORKING GROUP ON 
COMPLEMENTARY METHODS 
 
 
 
PREFACE  
 
 In September 1994, the International Council for Laboratory Animal Science 
(ICLAS), a non-govemmental organization for international cooperation in laboratory 
animal science, created a working group to promote complementary and alternative 
methods to reduce, refine and replace the use of laboratory animals. 
  
 A meeting of the ICLAS/CSIC Working Group on complementary methods was 
held in  Centro Regional de Salud  in Talavera de la Reina, Toledo, Spain, on Apri1 
28-29, 1995 under the chairmanship of Dr. Eduardo de la Peña, ICLAS Scientific 
Member for Spain.  
 
 The objective of this meeting was to obtain a list of recommendations to be 
presented to the ICLAS Governing Board and General Assembly that were held in 
Helsinki Finland on July 1-7,1995. Professor García Partida, President of the ICLAS 
Spanish committee, expressed his gratitude to all those who participated and stressed 
the significance of this report of the meeting.  
 
 
INTRODUCTION  
 
Dr. Eduardo de la Peña, coordinator of the ICLAS/CSIC working group 
on complementary methods, explained the format of the meeting at the start of 
the first session. The meeting was divided into six sessions. In each session 
(except for session six) a fifteen minute presentation by a speaker with ex- 
pertise on a specific topic was followed by a one hour discussion. A session 
rapporteur, a moderator and the secretary of the working group were respon- 
sible for preparing a document summarizing the major issues and conclusions 
of each session.  
 
 During session six, the rapporteurs of each previous session read their 
respective documents. Participants then discussed these reports in order to 
obtain a final report on the entire meeting.  
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GENERAL SUMMARY  
 
 The scientific rationale for alternatives development is based upon the 3 Rs 
concept of Russell and Burch-replacement, reduction and refinement. In 
general, the sessions focused on the harmonization of approaches to the 
development and validation of alternative methods. Validation was defined as 
the process whereby the relevance and reliability of a procedure are established 
for a particular purpose.  
 
 Several issues related to validation were discussed, including the need to 
define criteria, various different approaches, and problems associated with 
previous studies. Several recommendations focusing on the role ICLAS could 
take in fostering the development and implementation of alternatives were also 
formulated.  
 
Session I  
INTERNATIONAL HARMONIZATION OF TEST METHODS 
FOR HAZARD CHARACTERIZATION TAKING INTO 
ACCOUNT ANIMAL WELFARE ISSUES  
 
Speaker: Dr. Herman B. W. M. KOËTER  
 
Moderator: Dr. Pilar Goya  
 
Rapporteurs:  
 
Drs. Carmen Pueyo, Elina Valcarce, Bartolomé Ribas, and Ana Guadaño.  
 
 Discussion focused on the structure and role of the OECD, with special 
mention of the following aspects:  
 
 • The OECD serves as forum for discussion for its 25 member countries.  
 
 • The OECD functions to develop and update guidelines that are binding to 
all member countries and used as a reference in non-member countries.  
 
 • The OECD works to harmonize different assay methods, with goals of 
reducing animal use and avoiding unnecessary trade barriers by 
promoting mutual acceptance of data (MAD principle). 
 
 • Until now, no formal proposal for the adoption of any alternative test has 
been received by the OECD. The absence of harmonized validation 
criteria may have lead to outcomes of validation studies which are 
difficult to interpret and may have discouraged scientists from 
participating in formal validation studies.  
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 The harmonization of OECD guidelines for acute toxicity testing has re- 
sulted in a reduction of animal numbers used for the safety testing of 
chemicals, since results are now accepted internationally. Such harmonization 
and acceptance is also being achieved for pharmaceuticals where considerable 
numbers of animals are currently being used for toxicity testing. Since 1990, 
the International Conference on Harmonization (ICH) has made significant 
progress towards harmonizing test methods for pharmaceuticals between the 
USA, Japan and the EU. These activities take into account OECD's work in 
this area and proposals from harmonised test methods for pharmaceuticals will 
be considered for adoption as OECD Test Guidelines.  
 
Session II  
THE VALIDATION OF IN VITRO TOXICITY  
TEST PROCEDURES IN EUROPE  
 
Speaker: Prof. Horst SPIELMANN  
 
Moderator: Prof. Paulino García Partida  
 
Rapporteurs: Drs. Guillermo Repetto, Isabel Rodríguez and Kai Pelkonen  
 
 The relevance and reliability of a test or an assay should progressively be 
established during the development of a new test, from the beginning and 
throughout the process.  
 
 We have learned that some in vivo tests are not relevant and reliable for 
human toxicity assessment. This is not a major problem with respect to 
legislation, because such assessments are viewed as a "package" and there is a 
sufficient safety margin. However, the in vivo methods should be updated in 
the future.  
 
Session III  
IN VITRO ASSAYS JN THE DEVELOPMENT OF  
DRUGS AND CHEMICAL5  
 
Speaker: Dr. María José GOMEZ-LECHON  
 
Moderator: Dr. José V. Tarazona.  
 
Rapporteurs:  
 
Drs. Francisco O. González Menció, Angustias Herrera and Herman Koëter.  
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 In vitro assays have been steadily refined and are being used in the deve- 
lopment and toxicological testing of a number of different types of substances. 
Assays employing human cells are to be encouraged. Systems which use ge- 
netically engineered cells as models of human metabolism look particularly 
promising. The immortalization of cells is another promising field of activity, 
because of its potential for standardizing tests for differentiated cells of various 
types.  
 
 Standard cell lines are already available and could be used even more 
extensively than at present. Primary cultures are also relevant for certain uses. 
The main goal for the future is the development of reasonably standardized 
human cells with known metabolizing capacities. Knowledge of metabolism is 
also crucial in selecting appropriate animal species for toxicity testing.  
 
Session IV  
DEVELOPMENT OF ALTERNATIVE METHODS AND 
THE MODULAR APPROACH TO V ALIDATION  
 
Speaker: Prof. Alan M. GOLDBERG  
  
Moderator: Dr. Elina Valcarce 
  
Rapporteurs:  
 
Drs. José V. Tarazona, Covadonga Caballo and Michael Balls. 
 
 This presentation focused on the importance of knowledge of mechanisms 
of toxicity and the usefulness of alternatives in risk assessment. Questions 
raised during the presentation included the need for mechanistically-based 
tests, the incorporation of in vitro assays as a first approach in evaluating the 
safety of chemicals, therapeutic agents and other commercial products; the use 
of human cells and identifying regulatory requirements to encourage in vitro 
assays.  
 
 The presentation also provided an approach to validation that is based  
on fundamental principles and modeled after actual practice in other areas of 
methodology acceptance. It was recognized that the validation process is but 
one aspect of incorporation of in vitro approaches into safety evaluation and 
risk assessment.  
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Session V  
THE DEVELOPMENT, V ALIDATION AND ACCEPTANCE  
OF ALTERNATIVE METHODS  
 
Speaker: Prof. Michael BALLS 
 
Moderator: Dr. Carmen Barrueco. 
 
Rapporteurs:  
 
Drs. M. José Gómez Lechón, Jorge Zapatero, and Alan Goldberg.  
 
 This session dealt with the development, validation and acceptance of 
alternative methods in the context of Directive 86/609/EEC, which requires 
that experiments must "use the minimum number of animals" and "must cause 
the least pain, suffering, distress or lasting harm", which is consistent with 
providing satisfactory results, and that an experiment on animals "shall not be 
performed, if another scientifically satisfactory method of obtaining the result 
sought, not entailing the use of an animal, is reasonably and practicably 
available".  
 
 Where the replacement of animal tests required by regulatory require- 
ments is sought, formal validation is necessary. ECV AM (The European 
Centre for Validation of Alternative Methods) has been set up by the European 
Com- mission, with the principal task of coordinating the validation of 
alternative methods at the European Union level.  
 
 By the year 2000, the EU Member States aim to reduce the number of 
vertebrates used for experiments and other scientific purposes by 50%.  
 
 ECVAM has established criteria for the Centre's priority areas. The cri- 
teria are based on numbers of animals, amount of possible suffering, the likeli- 
hood that valid and acceptable replacement alternative methods can be found, 
and the needs of science and industry.  
 
CONCLUSIONS  
(collectively summarized for all five presentations)  
 
 Sequential approaches hold great promise for reducing animal numbers in 
toxicity testing. The use of in vitro assays should be encouraged, although in 
some cases they may be more time-consuming and expensive than in vivo 
assays.  
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 The acceptance of in vitro tests may be facilitated by conducting both in 
vitro and in vivo studies in parallel, until there is sufficient confidence that the 
in vitro tests could delete/replace their in vivo counterparts. 
 
 Although there will be many different approaches to methodology evalu- 
ation, several validation studies have shown that in many cases no more than 3-
5 experienced laboratories are required to validate a single method.  
 
 In many cases, the data from animal tests do not correspond to human 
responses. Therefore, the aim of alternative methods should not be to simply 
reduce the numbers of animals used, nor to replace the in vivo tests, but to 
develop new technologies and new strategies which will result in different, 
additional and more useful information.  
 
 There is a need for development of genetically modified cell lines which 
could result in metabolic mechanisms similar to those of human hepatocytes. 
Cell models, particularly of human origin, expressing organ-specific functions 
are necessary. For example, the use of human hepatocytes can facilitate the 
choice of more appropriate animal species for toxicity testing of particular 
compounds. There is also a need for the development of genetically modified 
cell lines with human biochemical capabilities.  
 
 Insufficient toxicological data exist for a considerable number of chemi- 
cals. To enable initial hazard/risk assessment of these chemicals within a rea- 
sonable time frame, relatively simple and rapid test methods are needed. For 
this purpose, non-animal (in vitro) methods should be considered as part of the 
initial safety assessment process.  
 
 In vitro studies should be incorporated into the development of new pro- 
ducts as early as possible.  
 
 Batteries of non-animal tests will be required. Mechanistically-based tests 
will always be preferable to correlative tests.  
 
 The optimization of protocols is an essential component prior to formal 
validation.  
 
 Replacement of single animal tests, although useful, is not necessary. The 
use of alternative methods cannot be reduced to simply reducing numbers of 
animals, but must focus on the development of new technologies resulting in 
new information.  
 
 There is an urgent need to establish courses for scientists and students, both 
on non-whole animal alternatives and on the ethics of animal experimentation 
in the biomedical sciences.  
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 The acceptance of new animal methods should be subjected to the same 
criteria as are applied to alternative methods. To establish an order of vali- 
dation areas, criteria must be developed to permit the most efficient use of 
resources and to produce validated methodology. In the area of vaccines and 
medicines, adequate biological understanding of mechanisms exists to provide 
a reasonable assurance that work in this area will lead to validated alternatives.  
 
RECOMMENDATIONS  
 
 ICLAS should take an active role in educating its members about de- 
velopments in ethics, statistics, and Three Rs alternative methods and their 
validation.  
 
 The ICLAS/CSIC workshop suggested that more fundamental research is 
essential to develop new non-animal methods. A reduction in animal use can 
be achieved if procedures involving animals are better designed and analyzed, 
and if stronger scientific justification is required before animal experiments are 
permitted.  
 
 The ICLAS/CSIC workshop recommends that new animal tests should be 
required to satisfy similar standards of validation as non-whole animal methods 
to achieve regulatory acceptance.  
 
 Although there are countries with minimal legislation on human and animal 
experimentation, changing the site of animal testing to those countries in order 
to avoid more stringent regulations in other nations is considered to be immoral 
and unethical. More stringent practices should be endorsed by all ICLAS 
member countries.  
 
 Dr. de la Peña closed the session by recommending that ICLAS use the 
terms "alternative" and "complementary" as synonyms. He also remarked on 
the need to make the scientific community aware of the development and use 
of complementary alternative methods and also of the need for effective 
diffusion of those methods. He also recognized the contributions of speakers, 
moderators, rapporteurs, translators, secretary members and all members of the 
ICLAS/CSIC Working Group on Complementary Methods to the creation of 
an excellent meeting. Special thanks were extended to ICLAS scientific mem- 
ber for Cuba, Dr. González Menció, the ICLAS national.member for Spain, 
Prof. Paulino García Partida, and Dr. Juan Atenza, director of the Centro 
Regional de Salud Pública, de Talavera de la Reina, for providing the facilities 
of the Center for the meeting.  
 
  
 
 
 
 
 
 
PARTICIPANTS  ADDRESSES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRUPO DE TRABAJO DE ICLAS/CSIC SOBRE METODOS COMPLEMENTARIOS 
 ICLAS/CSIC WORKING GROUP ON COMPLEMENTARY METHODS 
 
 
 
Consejo Superior de Investigaciones Científicas  
Comité Español del ICLAS/CSIC  
Centro de Salud Pública. Talavera de la Reina, España. 
ICLAS/CSIC WORKING GROUP ON COMPLEMENTARY METHODS                    
  
Dr. Juan Atenza 
Director 
Centro Regional de Salud Pública 
Ctra. Extremadura, km. 114,100 
Talavera de la Reina (Toledo) 
Fax.  925-804762 
Tlfo. 925-801056 
 
 
Dr. Michael Balls 
ECVAM 
Environment Institute 
I-21020 Ispra (VA) Italy 
Fax.  39-332-785336 
Tel.  39-332-785996 
e-mail: michael.balls@el.jro.it 
 
Dra. Carmen Barrueco 
Centro Nacional de Alimentación  
Instituto de Salud Carlos III 
Ctra. Majadahonda-Pozuelo 
28220 Majadahonda (Madrid) 
Fax. 91-6380613 
Tel. 91-6381111 
 
Dra. Covadonga Caballo Diéguez 
Subdirección de Sanidad Ambiental 
Ministerio de Sanidad y Consumo 
Paseo del Prado 18-20 
28071 Madrid 
Fax.  91-5964409 
 
Dr. Paulino García Partida 
Facultad de Veterinaria 
Universidad Complutense 
28040 Madrid 
Fax. 91-3943883 
Tlf. 91-3943850 
 
Lda. Mercedes García Vedia 
Centro de Ciencias Medioambientales. CSIC 
Serrano 115 dpdo. 
28006 Madrid 
Fax. 91-5640800 
Tel. 91-5625020 
 
 
 
Dr. Alan M. Goldberg 
CAAT . Center Alternative Animal 
Toxicology 
School of Hygiene and Public Health 
615 N. Wolfe Street Baltimore 
MD. 21205 USA 
Fax. 1-410-223-1603 
Tlf. 1-410-223-1692 
internet:caat@jhuhyg.sph.jhu.edu 
 
Dra. Mª José Gómez Lechón 
Unidad de Patología Experimental 
Cº Investigación Hospital La Fé 
Avda. Campoamor, 21 
46009 Valencia 
Fax.  96-3868718 
 
 
Dr. Francisco González Menció 
CENPALAB 
Bejucal. Habana. Cuba 
Fax. 537-336075 
 
 
Dra. Pilar Goya Laza 
Relaciones Internacionales. CSIC 
Serrano 117 
28006 Madrid 
Fax. 91-4113077 
 
 
Dra. Azucena González 
Centro de Ciencias Medioambientales. CSIC 
Serrano 115 dpdo. 
28006 Madrid 
Fax. 91-5640800 
Tel. 91-5625020 
 
 
Dra. Ana Guadaño 
Centro de Ciencias Medioambientales. CSIC 
Serrano 115 dpdo. 
28006 Madrid 
Fax. 91-5640800 
Tel. 91-5625020 
 
 
 
PARTICIPANTS  ADDRESSES 
 
Dra. Angustias Herrera Sebastián 
Subdirección de Sanidad Ambiental 
Ministerio de Sanidad y Consumo 
Paseo del Prado 18-20 
28071 Madrid 
Fax.  91-5964409 
 
 
Dr. Santiago Lago 
Vicesecretario 
Secretaría General del Plan I+D 
Rosario Pino 14-16 
28020 Madrid 
Tel. 91-3360423 
Fax. 91-3360435 
 
 
Dra. Adela López de Ceraín 
CIFA 
Universidad de Navarra 
Apdo. 273 
31080 Pamplona 
Fax. 948-105652 
Tel. 948-105653 
 
 
Dr. Herman B.W.M. Köeter 
OCDE. Environmental Health and Safety 
Division 
2 Rue Andre Pascal 
75775 Paris. Cedex 16 
Francia 
Fax.  33-1-45241675 
 
 
Dr. Kai Pelkonen 
Dept. Physiology 
University of Kuopio 
po/Box 1627 
70211 Kuopio, Finlandia 
Fax. 358-71-163963 / 358-71-2826236 
Tel. 358-71-163900 / 358-400-654343 
 
 
Dr. E. de la Peña 
Centro de Ciencias Medioambientales. CSIC 
Serrano 115 dpdo. 
28006 Madrid 
Fax. 91-5640800 
Tel. 91-5625020 
 
 
 
 
Dra. Carmen Pueyo de la Cuesta 
Dptº Genética 
Facultad de Ciencias 
Universidad de Córdoba 
14071 Córdoba 
Fax. 957-218606 
Tlf. 957-411211 
 
 
Dr. Guillermo Repetto Kuhn 
Instº Nacional Toxicología 
Apartado 863 
41080 Sevilla 
Fax.  954 370262 
Tel. 954 371233 
 
Dr. Bartolomé Ribas 
Instituto de Salud Carlos III 
Departamento de Toxicología 
28220 Majadahonda (Madrid) 
Fax. 91-6385992 
Tel. 91-6389911 
 
 
Dra. Mª Isabel Rodríguez LLopis 
GAIKER 
Parque Tecnológico de Zamudio, ed. 202 
Zamudio (Vizcaya) 
Fax. 94-4522323 
Tel. 94-4522236 
 
Dr. Horst Spielmann 
Zebet. Zentrastelle zur Erfassung und 
Bewertung von Ersatz- und 
Ergänzungsmethoden 
zum Tlerversuch 
Diedersdorfer Weg 1 
D-12277 Berlin, Alemania 
Fax. 49-30-8412-2958 
Tel. 49-30-8412-2270 
 
 
ICLAS/CSIC WORKING GROUP ON COMPLEMENTARY METHODS                    
  
Dr. Jose Vicente Tarazona 
Cº Investigación en Sanidad Animal 
INIA 
28130 Valdeolmos, Madrid 
Fax.  91-6202247 
Tlf:  91-6206300 
 
 
Dra. Elina Valcarce de Angulo 
Ministerio de Sanidad y Consumo 
Paseo del Prado 18-20 
28071 Madrid 
Fax  91-5964409 
 
 
Dr. Jorge Zapatero 
Centro Investigación y Desarrollo Aplicado 
Centro Industrial Santiga 
Argenters, 6 
08130- Sta. Perpetua de Moguda, Barcelona 
Fax. 93-7189667 
Tel. 93-7190361 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRANSLATORS 
Mr. Stephen J. Carlin 
Urbanización La Vega 
C/Los Olivos, 19 
28450 Collado Mediano (Madrid) 
Tel. 91-855-7370 
 
 
Ms. Anne Goslin 
C/Francisco Granizo, 1 
28224 Pozuelo de Alarcón (Madrid) 
Fax. 91-7159145 
Tel. 91-3524441 
 
 
 
SECRETARIA 
Dª Antonia Martínez López 
Centro de Ciencias Medioambientales. CSIC 
Serrano 115 dpdo. 
28006 Madrid 
Fax. 91-5640800 
Tel. 91-5625020 
